<!DOCTYPE html>
<html class="client-js"><head>
  <meta charset=UTF-8"UTF-8">
  <title>Sirolimus</title>
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <script>
    function importScript() { return 1 } // this is to avoid the error from site.js
  </script>
  <link rel="canonical" href="https://en.wikipedia.org/wiki/Sirolimus">
  <link href="../-/s/css_modules/ext.cite.ux-enhancements.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/ext.cite.ux-enhancements.css" rel="stylesheet" type="text/css" class="">
<link href="../-/s/css_modules/ext.cite.styles.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/ext.cite.styles.css" rel="stylesheet" type="text/css" class="">
<link href="../-/s/css_modules/fi000001.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/skins.minerva.base.reset|skins.minerva.content.styles|ext.cite.style|site.styles|mobile.app.pagestyles.android|mediawiki.page.gallery.styles|mediawiki.skinning.content.parsoid.css" rel="stylesheet" type="text/css" class="">
  <link href="../-/s/css_modules/style.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/style.css" rel="stylesheet" type="text/css" class=""><link href="../-/s/css_modules/content.parsoid.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/content.parsoid.css" rel="stylesheet" type="text/css" class=""><link href="../-/s/css_modules/inserted_style.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/inserted_style.css" rel="stylesheet" type="text/css" class="">
  <script src="../-/j/js_modules/script.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/script.js" class=""></script><script src="../-/j/js_modules/masonry.min.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/masonry.min.js" class=""></script><script src="../-/j/js_modules/article_list_home.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/article_list_home.js" class=""></script><script src="../-/j/js_modules/images_loaded.min.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/images_loaded.min.js" class=""></script><script src="../-/j/js_modules/node_module/details-element-polyfill/dist/details-element-polyfill.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/node_module/details-element-polyfill/dist/details-element-polyfill.js" class=""></script>
<link type="root" href=""></head>

<body class="mediawiki mw-hide-empty-elt ns-0 ns-subject stable skin-minerva action-view animations">
  <div id="mw-mf-viewport" class="feature-header-v2">
    <div id="mw-mf-page-center">
      <div id="content" class="mw-body">
        <a id="top"></a>
        <div id="bodyContent" class="content mw-parser-output">
          
          <div id="mw-content-text" style="direction: ltr;"><h1 class="section-heading" tabindex="0" aria-haspopup="true" data-section-id="0">
  <span class="mw-headline" id="title_0">Sirolimus</span>
</h1>
<div id="mf-section-0" class="mf-section-0" aria-pressed="true" aria-expanded="true">
  <p><b>Sirolimus</b>, also known as <b>rapamycin</b>, is a macrolide compound that is used  to coat coronary stents, prevent organ transplant rejection and treat a rare lung disease called lymphangioleiomyomatosis.<span class="mw-ref" id="cite_ref-Rapamune_Rx_info_4-0"><a href="#cite_note-Rapamune_Rx_info-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span><span class="mw-ref" id="cite_ref-Vezi_5-0"><a href="#cite_note-Vezi-5" style="counter-reset: mw-Ref 5;"><span class="mw-reflink-text">[5]</span></a></span><span class="mw-ref" id="cite_ref-Cypher_6-0"><a href="#cite_note-Cypher-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span> It has immunosuppressant functions in humans and is especially useful in preventing the rejection of kidney transplants. It inhibits activation of T cells and B cells by reducing their sensitivity to <a href="Interleukin_2.htm" tppabs="https://ptable.com/wiki/compounds/A/Interleukin-2" title="Interleukin-2" class="mw-redirect">interleukin-2</a> (IL-2) through mTOR inhibition.<span class="mw-ref" id="cite_ref-Mukherjee_2009_7-0"><a href="#cite_note-Mukherjee_2009-7" style="counter-reset: mw-Ref 7;"><span class="mw-reflink-text">[7]</span></a></span></p>


<span>

</span>
<p></p>
<table class="infobox" style="width:22em;border-spacing:2px;"><caption><span>Sirolimus</span></caption><tbody><tr><td colspan="2" style="text-align:center"><figure-inline><img src="../I/m/Sirolimus_structure.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Sirolimus_structure.svg.png" data-file-width="512" data-file-height="478" data-file-type="drawing" height="233" width="250"></figure-inline></td></tr><tr><td colspan="2" style="text-align:center"><figure-inline><img src="../I/m/Sirolimus-from-1C9H-3D-sticks.png" tppabs="https://ptable.com/wiki/compounds/I/m/Sirolimus-from-1C9H-3D-sticks.png" data-file-width="1100" data-file-height="993" data-file-type="bitmap" height="226" width="250"></figure-inline></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Clinical data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Trade names</th><td>Rapamune</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Other names</th><td>Rapamycin</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">License data</th><td><div class="plainlist">
<ul><li><small><abbr class="country-name">EU</abbr></small><span>&nbsp;</span>EMA:<span>&nbsp;</span><span><a href="javascript:if(confirm('http://www.ema.europa.eu/ema/index.jsp?curl=%2Fpages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=&searchTab=searchByKey&alreadyLoaded=true&isNewQuery=true&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&keywordSearch=Submit&searchType=inn&taxonomyPath=&treeNumber=&searchGenericType=generics&keyword=Sirolimus  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.ema.europa.eu/ema/index.jsp?curl=%2Fpages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=&searchTab=searchByKey&alreadyLoaded=true&isNewQuery=true&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&keywordSearch=Submit&searchType=inn&taxonomyPath=&treeNumber=&searchGenericType=generics&keyword=Sirolimus'" tppabs="http://www.ema.europa.eu/ema/index.jsp?curl=%2Fpages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=&searchTab=searchByKey&alreadyLoaded=true&isNewQuery=true&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&keywordSearch=Submit&searchType=inn&taxonomyPath=&treeNumber=&searchGenericType=generics&keyword=Sirolimus" class="external text external">by INN</a></span></li>
<li><small><abbr class="country-name">US</abbr></small><span>&nbsp;</span><span>FDA:<span>&nbsp;</span><a href="javascript:if(confirm('https://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&SearchTerm=Sirolimus&SearchType=BasicSearch  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&SearchTerm=Sirolimus&SearchType=BasicSearch'" tppabs="https://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&SearchTerm=Sirolimus&SearchType=BasicSearch" class="external text external">Sirolimus</a></span></li></ul></div>
</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Pregnancy<br>category</th><td><div class="plainlist">
<ul><li><small><abbr class="country-name">AU</abbr>:</small><span> </span>C<span> </span></li>
<li><small><abbr class="country-name">US</abbr>:</small><span> </span>C (Risk not ruled out)<span> </span></li></ul>

<ul></ul>
</div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Routes of<br>administration</th><td>Oral</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ATC code</th><td><div class="plainlist"><ul><li>L04AA10<span> </span>(<span><a href="javascript:if(confirm('https://www.whocc.no/atc_ddd_index/?code=L04AA10  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.whocc.no/atc_ddd_index/?code=L04AA10'" tppabs="https://www.whocc.no/atc_ddd_index/?code=L04AA10" class="external text external">WHO</a></span>)<span> </span>S01XA23<span> </span>(<span><a href="javascript:if(confirm('https://www.whocc.no/atc_ddd_index/?code=S01XA23  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.whocc.no/atc_ddd_index/?code=S01XA23'" tppabs="https://www.whocc.no/atc_ddd_index/?code=S01XA23" class="external text external">WHO</a></span>)</li></ul></div></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Legal status</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Legal status</th><td><div class="plainlist">
<ul><li><small><abbr class="country-name">US</abbr>:</small><span> </span>℞-only<span> </span></li></ul></div>
</td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Pharmacokinetic data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Bioavailability</th><td>14% (oral solution), lower with high-fat meals; 18% (tablet), higher with high-fat meals<span class="mw-ref" id="cite_ref-1"><a href="#cite_note-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Protein binding</th><td>92%</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Metabolism</th><td>Hepatic</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Elimination <span class="nowrap">half-life</span></th><td>57–63 hours<span class="mw-ref" id="cite_ref-Pubchem_Rapamycin_2-0"><a href="#cite_note-Pubchem_Rapamycin-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Excretion</th><td>Mostly faecal</td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Identifiers</th></tr><tr><td colspan="2" style="text-align:center"><div class="NavFrame collapsed" style="border: none; padding: 0;">
<div class="NavHead" style="font-size: 105%; background: transparent; text-align: left;">IUPAC name</div>
<ul class="NavContent" style="list-style: none none; margin-left: 0; word-break:break-all; text-align:left; padding-left:1.5em; text-indent:-1.5em; font-size: 105%; margin-top: 0; margin-bottom: 0; line-height: inherit;"><li style="line-height: inherit; margin: 0"><span style="font-size: 11px;">(1<i>R</i>,9<i>S</i>,12<i>S</i>,15<i>R</i>,16<i>E</i>,18<i>R</i>,19<i>R</i>,21<i>R</i>,23<i>S</i>,24<i>E</i>,26<i>E</i>,28<i>E</i>,<br>30<i>S</i>,32<i>S</i>,35<i>R</i>)-1,18-dihydroxy-12-{(2<i>R</i>)-1-[(1<i>S</i>,3<i>R</i>,<br>4<i>R</i>)-4-hydroxy-3-methoxycyclohexyl]-2-propanyl}-<br>19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-<br>11,36-dioxa-4-azatricyclo[30.3.1.0~4,9~]hexatria<br>conta-16,24,26,28-tetraene-2,3,10,14,20-pentone</span></li></ul>
</div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">CAS Number</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('http://www.commonchemistry.org/ChemicalDetail.aspx?ref=53123-88-9  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.commonchemistry.org/ChemicalDetail.aspx?ref=53123-88-9'" tppabs="http://www.commonchemistry.org/ChemicalDetail.aspx?ref=53123-88-9" class="external text external">53123-88-9</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">PubChem <span style="font-weight:normal"><abbr>CID</abbr></span></th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://pubchem.ncbi.nlm.nih.gov/compound/5284616  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubchem.ncbi.nlm.nih.gov/compound/5284616'" tppabs="https://pubchem.ncbi.nlm.nih.gov/compound/5284616" class="external text external">5284616</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">DrugBank</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.drugbank.ca/drugs/DB00877  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugbank.ca/drugs/DB00877'" tppabs="https://www.drugbank.ca/drugs/DB00877" class="external text external">DB00877</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ChemSpider</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('http://www.chemspider.com/Chemical-Structure.10482078.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.chemspider.com/Chemical-Structure.10482078.html'" tppabs="http://www.chemspider.com/Chemical-Structure.10482078.html" class="external text external">10482078</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">UNII</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=W36ZG6FT64  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=W36ZG6FT64'" tppabs="https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=W36ZG6FT64" class="external text external">W36ZG6FT64</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">KEGG</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.kegg.jp/entry/D00753  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.kegg.jp/entry/D00753'" tppabs="https://www.kegg.jp/entry/D00753" class="external text external">D00753</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ChEBI</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:9168  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:9168'" tppabs="https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:9168" class="external text external">CHEBI:9168</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ChEMBL</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL413  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL413'" tppabs="https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL413" class="external text external">ChEMBL413</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">PDB ligand</th><td><div class="plainlist"><ul><li>RAP (<span><a href="javascript:if(confirm('https://www.ebi.ac.uk/pdbe-srv/PDBeXplore/ligand/?ligand=RAP  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ebi.ac.uk/pdbe-srv/PDBeXplore/ligand/?ligand=RAP'" tppabs="https://www.ebi.ac.uk/pdbe-srv/PDBeXplore/ligand/?ligand=RAP" class="external text external">PDBe</a></span>, <span><a href="javascript:if(confirm('http://www.rcsb.org/pdb/search/smartSubquery.do?smartSearchSubtype=ChemCompIdQuery&chemCompId=RAP&polymericType=Any  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.rcsb.org/pdb/search/smartSubquery.do?smartSearchSubtype=ChemCompIdQuery&chemCompId=RAP&polymericType=Any'" tppabs="http://www.rcsb.org/pdb/search/smartSubquery.do?smartSearchSubtype=ChemCompIdQuery&chemCompId=RAP&polymericType=Any" class="external text external">RCSB<span>&nbsp;</span>PDB</a></span>)</li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">CompTox Dashboard <span style="font-weight:normal">(<abbr>EPA</abbr>)</span></th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://comptox.epa.gov/dashboard/DTXSID5023582  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://comptox.epa.gov/dashboard/DTXSID5023582'" tppabs="https://comptox.epa.gov/dashboard/DTXSID5023582" class="external text external">DTXSID5023582</a> <figure-inline class="mw-valign-text-top"><img src="../I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" data-file-width="20" data-file-height="20" data-file-type="drawing" height="10" width="10"></figure-inline></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;"><span>ECHA InfoCard</span></th><td><a href="javascript:if(confirm('https://echa.europa.eu/substance-information/-/substanceinfo/100.107.147  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://echa.europa.eu/substance-information/-/substanceinfo/100.107.147'" tppabs="https://echa.europa.eu/substance-information/-/substanceinfo/100.107.147" class="external text external">100.107.147</a> <figure-inline class="mw-valign-text-top"><img src="../I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" data-file-width="20" data-file-height="20" data-file-type="drawing" height="10" width="10"></figure-inline></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Chemical and physical data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Formula</th><td><span>C</span><sub>51</sub><span>H</span><sub>79</sub><span>N</span><span>O</span><sub>13</sub></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Molar mass</th><td><span class="nowrap">914.187</span><span>&nbsp;</span>g·mol<sup>−1</sup></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">3D model (JSmol)</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://chemapps.stolaf.edu/jmol/jmol.php?model=O%5BC%40%40H%5D1CC%5BC%40H%5D%28C%5BC%40H%5D1OC%29C%5BC%40%40H%5D%28C%29%5BC%40%40H%5D4CC%28%3DO%29%5BC%40H%5D%28C%29%2FC%3DC%28%5CC%29%5BC%40%40H%5D%28O%29%5BC%40%40H%5D%28OC%29C%28%3DO%29%5BC%40H%5D%28C%29C%5BC%40H%5D%28C%29%5CC%3DC%5CC%3DC%5CC%3DC%28%2FC%29%5BC%40%40H%5D%28OC%29C%5BC%40%40H%5D2CC%5BC%40%40H%5D%28C%29%5BC%40%40%5D%28O%29%28O2%29C%28%3DO%29C%28%3DO%29N3CCCC%5BC%40H%5D3C%28%3DO%29O4  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://chemapps.stolaf.edu/jmol/jmol.php?model=O%5BC%40%40H%5D1CC%5BC%40H%5D%28C%5BC%40H%5D1OC%29C%5BC%40%40H%5D%28C%29%5BC%40%40H%5D4CC%28%3DO%29%5BC%40H%5D%28C%29%2FC%3DC%28%5CC%29%5BC%40%40H%5D%28O%29%5BC%40%40H%5D%28OC%29C%28%3DO%29%5BC%40H%5D%28C%29C%5BC%40H%5D%28C%29%5CC%3DC%5CC%3DC%5CC%3DC%28%2FC%29%5BC%40%40H%5D%28OC%29C%5BC%40%40H%5D2CC%5BC%40%40H%5D%28C%29%5BC%40%40%5D%28O%29%28O2%29C%28%3DO%29C%28%3DO%29N3CCCC%5BC%40H%5D3C%28%3DO%29O4'" tppabs="https://chemapps.stolaf.edu/jmol/jmol.php?model=O%5BC%40%40H%5D1CC%5BC%40H%5D%28C%5BC%40H%5D1OC%29C%5BC%40%40H%5D%28C%29%5BC%40%40H%5D4CC%28%3DO%29%5BC%40H%5D%28C%29%2FC%3DC%28%5CC%29%5BC%40%40H%5D%28O%29%5BC%40%40H%5D%28OC%29C%28%3DO%29%5BC%40H%5D%28C%29C%5BC%40H%5D%28C%29%5CC%3DC%5CC%3DC%5CC%3DC%28%2FC%29%5BC%40%40H%5D%28OC%29C%5BC%40%40H%5D2CC%5BC%40%40H%5D%28C%29%5BC%40%40%5D%28O%29%28O2%29C%28%3DO%29C%28%3DO%29N3CCCC%5BC%40H%5D3C%28%3DO%29O4" class="external text external">Interactive image</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Solubility in water</th><td>0.0026 <span class="mw-ref" id="cite_ref-3"><a href="#cite_note-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span><span>&nbsp;</span>mg/mL (20<span>&nbsp;</span>°C)</td></tr><tr><td colspan="2" style="text-align:center"><div class="NavFrame collapsed" style="border: none; padding: 0;">
<div class="NavHead" style="font-size: 105%; background: transparent; text-align: left;">SMILES</div>
<ul class="NavContent" style="list-style: none none; margin-left: 0; word-break:break-all; font-size: 105%; margin-top: 0; margin-bottom: 0; line-height: inherit;"><li style="line-height: inherit; margin: 0"><div style="word-wrap:break-word; text-indent:-1.5em; text-align:left; padding-left:1.5em; font-size:11px; line-height:120%;">O[C@@H]1CC[C@H](C[C@H]1OC)C[C@@H](C)[C@@H]4CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)[C@@H](OC)C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N3CCCC[C@H]3C(=O)O4</div></li></ul>
</div></td></tr><tr><td colspan="2" style="text-align:center"><div class="NavFrame collapsed" style="border: none; padding: 0;">
<div class="NavHead" style="font-size: 105%; background: transparent; text-align: left;">InChI</div>
<ul class="NavContent" style="list-style: none none; margin-left: 0; word-break:break-all; font-size: 105%; margin-top: 0; margin-bottom: 0; line-height: inherit;"><li style="line-height: inherit; margin: 0"><div style="word-wrap:break-word; text-indent:-1.5em; text-align:left; padding-left:1.5em; font-size:11px; line-height:120%;">InChI=1S/C51H79NO13/c1-30-16-12-11-13-17-31(2)42(61-8)28-38-21-19-36(7)51(60,65-38)48(57)49(58)52-23-15-14-18-39(52)50(59)64-43(33(4)26-37-20-22-40(53)44(27-37)62-9)29-41(54)32(3)25-35(6)46(56)47(63-10)45(55)34(5)24-30/h11-13,16-17,25,30,32-34,36-40,42-44,46-47,53,56,60H,14-15,18-24,26-29H2,1-10H3/b13-11+,16-12+,31-17+,35-25+/t30-,32-,33-,34-,36-,37+,38+,39+,40-,42+,43+,44-,46-,47+,51-/m1/s1<sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></div></li><li style="line-height: inherit; margin: 0"><div style="word-wrap:break-word; text-indent:-1.5em; text-align:left; padding-left:1.5em; font-size:11px; line-height:120%;">Key:QFJCIRLUMZQUOT-HPLJOQBZSA-N<sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></div></li></ul>
</div></td></tr><tr><td colspan="2" style="text-align:center"><style data-mw-deduplicate="TemplateStyles:r886047488">.mw-parser-output .nobold{font-weight:normal}</style><span class="nobold"><span>&nbsp;</span><span>&nbsp;</span><span class="reflink  nourlexpansion"><a href="javascript:if(confirm('https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=732542693&page2=Sirolimus  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=732542693&page2=Sirolimus'" tppabs="https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=732542693&page2=Sirolimus" class="external text external">(verify)</a></span></span></td></tr></tbody></table>

<p>It is produced by the bacterium <i>Streptomyces hygroscopicus</i> and was isolated for the first time in 1972 by <span class="new">Surendra Nath Sehgal</span> and colleagues from samples of <i>Streptomyces hygroscopicus</i> found on Easter Island.<span class="mw-ref" id="cite_ref-8"><a href="#cite_note-8" style="counter-reset: mw-Ref 8;"><span class="mw-reflink-text">[8]</span></a></span><span class="mw-ref" id="cite_ref-RapamycinOrigin_9-0"><a href="#cite_note-RapamycinOrigin-9" style="counter-reset: mw-Ref 9;"><span class="mw-reflink-text">[9]</span></a></span> The compound was originally named rapamycin after the native name of the island, Rapa Nui.<span class="mw-ref" id="cite_ref-Vezi_5-1"><a href="#cite_note-Vezi-5" style="counter-reset: mw-Ref 5;"><span class="mw-reflink-text">[5]</span></a></span> Sirolimus was initially developed as an antifungal agent. However, this use was abandoned when it was discovered to have potent immunosuppressive and antiproliferative properties due to its ability to inhibit mTOR. It was approved by the US Food and Drug Administration in September 1999 and is marketed under the trade name <b>Rapamune</b> by Pfizer (formerly by Wyeth).</p>


</div><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Medical_uses">Medical uses</h2></summary>
    
<p>Sirolimus is indicated for the prevention of organ transplant rejection and for the treatment of lymphangioleiomyomatosis (LAM).<span class="mw-ref" id="cite_ref-Rapamune_Rx_info_4-1"><a href="#cite_note-Rapamune_Rx_info-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span></p>


    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Prevention_of_transplant_rejection">Prevention of transplant rejection</h3></summary>
    

<p>The chief advantage sirolimus has over calcineurin inhibitors is its low toxicity toward kidneys. Transplant patients maintained on calcineurin inhibitors long-term tend to develop impaired kidney function or even kidney failure; this can be avoided by using sirolimus instead. It is particularly advantageous in patients with kidney transplants for hemolytic-uremic syndrome, as this disease is likely to recur in the transplanted kidney if a calcineurin-inhibitor is used. However, on 7 October 2008, the FDA approved safety labeling revisions for sirolimus to warn of the risk for decreased renal function associated with its use.<span class="mw-ref" id="cite_ref-10"><a href="#cite_note-10" style="counter-reset: mw-Ref 10;"><span class="mw-reflink-text">[10]</span></a></span><span class="mw-ref" id="cite_ref-11"><a href="#cite_note-11" style="counter-reset: mw-Ref 11;"><span class="mw-reflink-text">[11]</span></a></span> In 2009, the FDA notified healthcare professionals that a clinical trial conducted by Wyeth showed an increased mortality in stable liver transplant patients after switching from a calcineurin inhibitor-based immunosuppressive regimen to sirolimus.<span class="mw-ref" id="cite_ref-12"><a href="#cite_note-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></span></p>

<p>Sirolimus can also be used alone, or in conjunction with a calcineurin inhibitor (such as <a href="Tacrolimus.htm" tppabs="https://ptable.com/wiki/compounds/A/Tacrolimus" title="Tacrolimus">tacrolimus</a>), and/or <a href="Mycophenolate_mofetil.htm" tppabs="https://ptable.com/wiki/compounds/A/Mycophenolate_mofetil" title="Mycophenolate mofetil" class="mw-redirect">mycophenolate mofetil</a>, to provide steroid-free immunosuppression regimens. Impaired wound healing and thrombocytopenia are a possible side effects of sirolimus; therefore, some transplant centers prefer not to use it immediately after the transplant operation, but instead administer it only after a period of weeks or months. Its optimal role in immunosuppression has not yet been determined, and it remains the subject of a number of ongoing clinical trials.<span class="mw-ref" id="cite_ref-Mukherjee_2009_7-1"><a href="#cite_note-Mukherjee_2009-7" style="counter-reset: mw-Ref 7;"><span class="mw-reflink-text">[7]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Lymphangioleiomyomatosis">Lymphangioleiomyomatosis</h3></summary>
    
<p>On 28 May 2015, the FDA approved sirolimus to treat lymphangioleiomyomatosis (LAM), a rare, progressive lung disease that primarily affects women of childbearing age. This made sirolimus the first drug approved to treat this disease.<span class="mw-ref" id="cite_ref-FDA_2015_13-0"><a href="#cite_note-FDA_2015-13" style="counter-reset: mw-Ref 13;"><span class="mw-reflink-text">[13]</span></a></span> LAM involves lung tissue infiltration with smooth muscle-like cells with mutations of the tuberous sclerosis complex gene (TSC2). Loss of TSC2 gene function activates the mTOR signaling pathway, resulting in the release of lymphangiogenic growth factors. Sirolimus blocks this pathway.<span class="mw-ref" id="cite_ref-Rapamune_Rx_info_4-2"><a href="#cite_note-Rapamune_Rx_info-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span></p>

<p>The safety and efficacy of sirolimus treatment of LAM were investigated in clinical trials that compared sirolimus treatment with a placebo group in 89 patients for 12 months. The patients were observed for 12 months after the treatment had ended. The most commonly reported side effects of sirolimus treatment of LAM were mouth and lip ulcers, diarrhea, abdominal pain, nausea, sore throat, acne, chest pain, leg swelling, upper respiratory tract infection, headache, dizziness, muscle pain and elevated <a href="Cholesterol.htm" tppabs="https://ptable.com/wiki/compounds/A/Cholesterol" title="Cholesterol">cholesterol</a>. Serious side effects including hypersensitivity and swelling (edema) have been observed in renal transplant patients.<span class="mw-ref" id="cite_ref-FDA_2015_13-1"><a href="#cite_note-FDA_2015-13" style="counter-reset: mw-Ref 13;"><span class="mw-reflink-text">[13]</span></a></span></p>

<p>While sirolimus was considered for treatment of LAM, it received orphan product designation status because LAM is a rare condition. Development for the product was partially supported by the FDA Orphan Products Grants Program, which provides grants for clinical studies on safety and/or effectiveness of products for use in rare diseases or conditions.<span class="mw-ref" id="cite_ref-FDA_2015_13-2"><a href="#cite_note-FDA_2015-13" style="counter-reset: mw-Ref 13;"><span class="mw-reflink-text">[13]</span></a></span></p>

<p>The safety of LAM treatment by sirolimus in patients younger than 18 years old has not been tested.<span class="mw-ref" id="cite_ref-Rapamune_Rx_info_4-3"><a href="#cite_note-Rapamune_Rx_info-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Coronary_stent_coating">Coronary stent coating</h3></summary>
    

<p>The antiproliferative effect of sirolimus has also been used in conjunction with coronary stents to prevent restenosis in coronary arteries following balloon angioplasty.  The sirolimus is formulated in a polymer coating that affords controlled release through the healing period following coronary intervention.  Several large clinical studies have demonstrated lower restenosis rates in patients treated with sirolimus-eluting stents when compared to bare-metal stents, resulting in fewer repeat procedures. A sirolimus-eluting coronary stent was marketed by Cordis, a division of Johnson &amp; Johnson, under the tradename Cypher.<span class="mw-ref" id="cite_ref-Cypher_6-1"><a href="#cite_note-Cypher-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span>  However, this kind of stent may also increase the risk of vascular thrombosis.<span class="mw-ref" id="cite_ref-Shuchman_14-0"><a href="#cite_note-Shuchman-14" style="counter-reset: mw-Ref 14;"><span class="mw-reflink-text">[14]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Venous_malformations">Venous malformations</h3></summary>
    
<p>Sirolimus is used to treat venous malformations. Treatment with sirolimus can decrease pain and the fullness of venous malformations, improve coagulation levels, and slow the growth of abnormal lymphatic vessels. <span class="mw-ref" id="cite_ref-15"><a href="#cite_note-15" style="counter-reset: mw-Ref 15;"><span class="mw-reflink-text">[15]</span></a></span> Sirolimus is a relatively new medical therapy for the treatment of vascular malformations,  <span class="mw-ref" id="cite_ref-16"><a href="#cite_note-16" style="counter-reset: mw-Ref 16;"><span class="mw-reflink-text">[16]</span></a></span> in recent years, sirolimus has emerged as a new medical treatment option for both vascular tumors and vascular malformations, as a mammalian target of rapamycin (mTOR), capable of integrating signals from the PI3K/AKT pathway to coordinate proper cell growth and proliferation. Hence, sirolimus is ideal for “proliferative” vascular tumors through the control of tissue overgrowth disorders caused by inappropriate activation of the PI3K/AKT/mTOR pathway as an antiproliferative agent. <span class="mw-ref" id="cite_ref-17"><a href="#cite_note-17" style="counter-reset: mw-Ref 17;"><span class="mw-reflink-text">[17]</span></a></span></p>

<p>Sirolimus is used especially to treat lymphatic malformation.</p>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Contraindications">Contraindications</h2></summary>
    
<p>Sirolimus is contraindicated in individuals with a known hypersensitivity to the drug.<span class="mw-ref" id="cite_ref-Rapamune_Rx_info_4-4"><a href="#cite_note-Rapamune_Rx_info-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Adverse_effects">Adverse effects</h2></summary>
    
<p>The most common adverse reactions (≥30% occurrence, leading to a 5% treatment discontinuation rate) observed with sirolimus in clinical studies of organ rejection prophylaxis in individuals with kidney transplants include: peripheral edema, hypercholesterolemia, abdominal pain, headache, nausea, diarrhea, pain, constipation, hypertriglyceridemia, hypertension, increased <a href="Creatinine.htm" tppabs="https://ptable.com/wiki/compounds/A/Creatinine" title="Creatinine">creatinine</a>, fever, urinary tract infection, anemia, arthralgia, and thrombocytopenia.<span class="mw-ref" id="cite_ref-Rapamune_Rx_info_4-5"><a href="#cite_note-Rapamune_Rx_info-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span></p>

<p>The most common adverse reactions (≥20% occurrence, leading to an 11% treatment discontinuation rate) observed with sirolimus in clinical studies for the treatment of lymphangioleiomyomatosis are: peripheral edema, hypercholesterolemia, abdominal pain, headache, nausea, diarrhea, chest pain, stomatitis, nasopharyngitis, acne, upper respiratory tract infection, dizziness, and myalgia.<span class="mw-ref" id="cite_ref-Rapamune_Rx_info_4-6"><a href="#cite_note-Rapamune_Rx_info-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span></p>

<p>The following adverse effects occurred in 3–20% of individuals taking sirolimus for organ rejection prophylaxis following a kidney transplant:<span class="mw-ref" id="cite_ref-Rapamune_Rx_info_4-7"><a href="#cite_note-Rapamune_Rx_info-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span></p>
<table class="wikitable">
<tbody><tr><th>System</th>
<th>Adverse effects</th></tr>
<tr>
<td>Body as a Whole</td><td>Sepsis, lymphocele, herpes zoster infection, herpes simplex infection</td></tr>
<tr>
<td>Cardiovascular</td><td>Venous thromboembolism (pulmonary embolism and deep venous thrombosis), rapid heart rate</td></tr>
<tr>
<td>Digestive</td><td>Stomatitis</td></tr>
<tr>
<td>Hematologic/Lymphatic</td><td>Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS), leukopenia</td></tr>
<tr>
<td>Metabolic</td><td>Abnormal healing, increased lactic dehydrogenase (LDH), hypokalemia, diabetes</td></tr>
<tr>
<td>Musculoskeletal</td><td>Bone necrosis</td></tr>
<tr>
<td>Respiratory</td><td>Pneumonia, epistaxis</td></tr>
<tr>
<td>Skin</td><td>Melanoma, squamous cell carcinoma, basal cell carcinoma</td></tr>
<tr>
<td>Urogenital</td><td>Pyelonephritis, ovarian cysts, menstrual disorders (amenorrhea and menorrhagia)</td></tr>
</tbody></table>


    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Diabetes-like_symptoms">Diabetes-like symptoms</h3></summary>
    
<p>While sirolimus inhibition of mTORC1 appears to mediate the drug's benefits, it also inhibits mTORC2, which results in diabetes-like symptoms.<span class="mw-ref" id="cite_ref-18"><a href="#cite_note-18" style="counter-reset: mw-Ref 18;"><span class="mw-reflink-text">[18]</span></a></span> This includes decreased glucose tolerance and insensitivity to insulin.<span class="mw-ref" id="cite_ref-19"><a href="#cite_note-19" style="counter-reset: mw-Ref 19;"><span class="mw-reflink-text">[19]</span></a></span> Sirolimus treatment may additionally increase the risk of type 2 diabetes.<span class="mw-ref" id="cite_ref-20"><a href="#cite_note-20" style="counter-reset: mw-Ref 20;"><span class="mw-reflink-text">[20]</span></a></span> In mouse studies, these symptoms can be avoided through the use of alternate dosing regimens or analogs such as <a href="Everolimus.htm" tppabs="https://ptable.com/wiki/compounds/A/Everolimus" title="Everolimus">everolimus</a> or <a href="Temsirolimus.htm" tppabs="https://ptable.com/wiki/compounds/A/Temsirolimus" title="Temsirolimus">temsirolimus</a>.<span class="mw-ref" id="cite_ref-21"><a href="#cite_note-21" style="counter-reset: mw-Ref 21;"><span class="mw-reflink-text">[21]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Lung_toxicity">Lung toxicity</h3></summary>
    
<p>Lung toxicity is a serious complication associated with sirolimus therapy,<span class="mw-ref" id="cite_ref-ReferenceA_22-0"><a href="#cite_note-ReferenceA-22" style="counter-reset: mw-Ref 22;"><span class="mw-reflink-text">[22]</span></a></span><span class="mw-ref" id="cite_ref-23"><a href="#cite_note-23" style="counter-reset: mw-Ref 23;"><span class="mw-reflink-text">[23]</span></a></span><span class="mw-ref" id="cite_ref-24"><a href="#cite_note-24" style="counter-reset: mw-Ref 24;"><span class="mw-reflink-text">[24]</span></a></span><span class="mw-ref" id="cite_ref-25"><a href="#cite_note-25" style="counter-reset: mw-Ref 25;"><span class="mw-reflink-text">[25]</span></a></span><span class="mw-ref" id="cite_ref-26"><a href="#cite_note-26" style="counter-reset: mw-Ref 26;"><span class="mw-reflink-text">[26]</span></a></span><span class="mw-ref" id="cite_ref-27"><a href="#cite_note-27" style="counter-reset: mw-Ref 27;"><span class="mw-reflink-text">[27]</span></a></span><span class="mw-ref" id="cite_ref-28"><a href="#cite_note-28" style="counter-reset: mw-Ref 28;"><span class="mw-reflink-text">[28]</span></a></span> especially in the case of lung transplants.<span class="mw-ref" id="cite_ref-29"><a href="#cite_note-29" style="counter-reset: mw-Ref 29;"><span class="mw-reflink-text">[29]</span></a></span> The mechanism of the interstitial pneumonitis caused by sirolimus and other macrolide MTOR inhibitors is unclear, and may have nothing to do with the mTOR pathway.<span class="mw-ref" id="cite_ref-30"><a href="#cite_note-30" style="counter-reset: mw-Ref 30;"><span class="mw-reflink-text">[30]</span></a></span><span class="mw-ref" id="cite_ref-31"><a href="#cite_note-31" style="counter-reset: mw-Ref 31;"><span class="mw-reflink-text">[31]</span></a></span><span class="mw-ref" id="cite_ref-32"><a href="#cite_note-32" style="counter-reset: mw-Ref 32;"><span class="mw-reflink-text">[32]</span></a></span> The interstitial pneumonitis is not dose-dependent, but is more common in patients with underlying lung disease.<span class="mw-ref" id="cite_ref-ReferenceA_22-1"><a href="#cite_note-ReferenceA-22" style="counter-reset: mw-Ref 22;"><span class="mw-reflink-text">[22]</span></a></span><span class="mw-ref" id="cite_ref-33"><a href="#cite_note-33" style="counter-reset: mw-Ref 33;"><span class="mw-reflink-text">[33]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Lowered_effectiveness_of_immune_system">Lowered effectiveness of immune system</h3></summary>
    
<p>There have been warnings about the use of sirolimus in transplants, where it may increase mortality due to an increased risk of infections.<span class="mw-ref" id="cite_ref-Rapamune_Rx_info_4-8"><a href="#cite_note-Rapamune_Rx_info-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span><span class="mw-ref" id="cite_ref-DailyMed_34-0"><a href="#cite_note-DailyMed-34" style="counter-reset: mw-Ref 34;"><span class="mw-reflink-text">[34]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Cancer_risk">Cancer risk</h3></summary>
    
<p>According to the FDA prescribing information, sirolimus may increase an individual's risk for contracting skin cancers from exposure to sunlight or UV radiation, and risk of developing lymphoma.<span class="mw-ref" id="cite_ref-Rapamune_Rx_info_4-9"><a href="#cite_note-Rapamune_Rx_info-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span> In studies, the skin cancer risk under sirolimus was lower than under other immunosuppressants such as <a href="Azathioprine.htm" tppabs="https://ptable.com/wiki/compounds/A/Azathioprine" title="Azathioprine">azathioprine</a> and calcineurin inhibitors, and lower than under placebo.<span class="mw-ref" id="cite_ref-35"><a href="#cite_note-35" style="counter-reset: mw-Ref 35;"><span class="mw-reflink-text">[35]</span></a></span><span class="mw-ref" id="cite_ref-36"><a href="#cite_note-36" style="counter-reset: mw-Ref 36;"><span class="mw-reflink-text">[36]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Impaired_wound_healing">Impaired wound healing</h3></summary>
    
<p>Individuals taking sirolimus are at increased risk of experiencing impaired or delayed wound healing, particularly if they have a body mass index in excess of 30<span>&nbsp;</span>kg/m<sup>2</sup> (classified as obese).<span class="mw-ref" id="cite_ref-Rapamune_Rx_info_4-10"><a href="#cite_note-Rapamune_Rx_info-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span></p>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Interactions">Interactions</h2></summary>
    
<p>Sirolimus is metabolized by the CYP3A4 enzyme and is a substrate of the P-glycoprotein (P-gp) efflux pump; hence, inhibitors of either protein may increase sirolimus concentrations in blood plasma, whereas inducers of CYP3A4 and P-gp may decrease sirolimus concentrations in blood plasma.<span class="mw-ref" id="cite_ref-Rapamune_Rx_info_4-11"><a href="#cite_note-Rapamune_Rx_info-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Pharmacology">Pharmacology</h2></summary>
    

    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Pharmacodynamics">Pharmacodynamics</h3></summary>
    

<p>Unlike the similarly named <a href="Tacrolimus.htm" tppabs="https://ptable.com/wiki/compounds/A/Tacrolimus" title="Tacrolimus">tacrolimus</a>, sirolimus is not a calcineurin inhibitor, but it has a similar suppressive effect on the immune system. Sirolimus inhibits IL-2 and other cytokine receptor-dependent signal transduction mechanisms, via action on mTOR, and thereby blocks activation of T and B cells. Ciclosporin and tacrolimus inhibit the secretion of IL-2, by inhibiting calcineurin.<span class="mw-ref" id="cite_ref-Mukherjee_2009_7-2"><a href="#cite_note-Mukherjee_2009-7" style="counter-reset: mw-Ref 7;"><span class="mw-reflink-text">[7]</span></a></span></p>

<p>The mode of action of sirolimus is to bind the cytosolic protein FK-binding protein 12 (FKBP12) in a manner similar to tacrolimus. Unlike the tacrolimus-FKBP12 complex, which inhibits calcineurin (PP2B), the sirolimus-FKBP12 complex inhibits the mTOR (mammalian Target Of Rapamycin, rapamycin being another name for sirolimus) pathway by directly binding to mTOR Complex 1 (mTORC1).<span class="mw-ref" id="cite_ref-Mukherjee_2009_7-3"><a href="#cite_note-Mukherjee_2009-7" style="counter-reset: mw-Ref 7;"><span class="mw-reflink-text">[7]</span></a></span></p>

<p>mTOR has also been called FRAP (FKBP-rapamycin-associated protein), RAFT (rapamycin and FKBP target), RAPT1, or SEP.  The earlier names FRAP and RAFT were coined to reflect the fact that sirolimus must bind FKBP12 first, and only the FKBP12-sirolimus complex can bind mTOR. However, mTOR is now the widely accepted name, since Tor was first discovered via genetic and molecular studies of sirolimus-resistant mutants of <i>Saccharomyces cerevisiae</i> that identified FKBP12, Tor1, and Tor2 as the targets of sirolimus and provided robust support that the FKBP12-sirolimus complex binds to and inhibits Tor1 and Tor2.<span class="mw-ref" id="cite_ref-Heitman_1991_37-0"><a href="#cite_note-Heitman_1991-37" style="counter-reset: mw-Ref 37;"><span class="mw-reflink-text">[37]</span></a></span><span class="mw-ref" id="cite_ref-Mukherjee_2009_7-4"><a href="#cite_note-Mukherjee_2009-7" style="counter-reset: mw-Ref 7;"><span class="mw-reflink-text">[7]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Pharmacokinetics">Pharmacokinetics</h3></summary>
    

<p>Sirolimus is metabolized by the CYP3A4 enzyme and is a substrate of the P-glycoprotein (P-gp) efflux pump.<span class="mw-ref" id="cite_ref-Rapamune_Rx_info_4-12"><a href="#cite_note-Rapamune_Rx_info-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span> It has an elimination half-life of 57–63<span>&nbsp;</span>hours.<span class="mw-ref" id="cite_ref-Pubchem_Rapamycin_2-1"><a href="#cite_note-Pubchem_Rapamycin-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span></p>

<p>The absorption of sirolimus into the blood stream from the intestine varies widely between patients, with some patients having up to eight times more exposure than others for the same dose. Drug levels are, therefore, taken to make sure patients get the right dose for their condition.<span class="mw-ref" id="cite_ref-Mukherjee_2009_7-5"><a href="#cite_note-Mukherjee_2009-7" style="counter-reset: mw-Ref 7;"><span class="mw-reflink-text">[7]</span></a></span> This is determined by taking a blood sample before the next dose, which gives the trough level. However, good correlation is noted between trough concentration levels and drug exposure, known as area under the concentration-time curve, for both sirolimus (SRL) and tacrolimus (TAC) (SRL: r2 = 0.83; TAC: r2 = 0.82), so only one level need be taken to know its pharmacokinetic (PK) profile. PK profiles of SRL and of TAC are unaltered by simultaneous administration. Dose-corrected drug exposure of TAC correlates with SRL (r2 = 0.8), so patients have similar bioavailability of both.<span class="mw-ref" id="cite_ref-38"><a href="#cite_note-38" style="counter-reset: mw-Ref 38;"><span class="mw-reflink-text">[38]</span></a></span></p>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Chemistry">Chemistry</h2></summary>
    

<p>Sirolimus is a natural product and macrocyclic lactone.<span class="mw-ref" id="cite_ref-Pubchem_Rapamycin_2-3"><a href="#cite_note-Pubchem_Rapamycin-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span></p>


    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Biosynthesis">Biosynthesis</h3></summary>
    
<p>The biosynthesis of the rapamycin core is accomplished by a type I polyketide synthase (PKS) in conjunction with a nonribosomal peptide synthetase (NRPS). The domains responsible for the biosynthesis of the linear polyketide of rapamycin are organized into three multienzymes, RapA, RapB, and RapC, which contain a total of 14 modules (figure 1). The three multienzymes are organized such that the first four modules of polyketide chain elongation are in RapA, the following six modules for continued elongation are in RapB, and the final four modules to complete the biosynthesis of the linear polyketide are in RapC.<span class="mw-ref" id="cite_ref-Rapamycin_domains_and_primary_genes_39-0"><a href="#cite_note-Rapamycin_domains_and_primary_genes-39" style="counter-reset: mw-Ref 39;"><span class="mw-reflink-text">[39]</span></a></span> Then, the linear polyketide is modified by the NRPS, RapP, which attaches L-pipecolate to the terminal end of the polyketide, and then cyclizes the molecule, yielding the unbound product, prerapamycin.<span class="mw-ref" id="cite_ref-prerapamycin_40-0"><a href="#cite_note-prerapamycin-40" style="counter-reset: mw-Ref 40;"><span class="mw-reflink-text">[40]</span></a></span></p>
<div class="thumb tnone" style="margin-left:auto;margin-right:auto;overflow:hidden;width:auto;max-width:1328px"><div class="thumbinner"><div class="noresize" style="overflow:auto"><figure-inline><img src="../I/m/Domain_organization_of_PKS_of_rapamycin_and_biosynthetic_intermediates.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Domain_organization_of_PKS_of_rapamycin_and_biosynthetic_intermediates.svg.png" data-file-width="1708" data-file-height="930" data-file-type="drawing" height="719" width="1320"></figure-inline></div><div class="thumbcaption">Figure 1: Domain organization of PKS of rapamycin and biosynthetic intermediates</div></div></div>
<style data-mw-deduplicate="TemplateStyles:r923042769/mw-parser-output/.tmulti">.mw-parser-output .tmulti .thumbinner{display:flex;flex-direction:column}.mw-parser-output .tmulti .trow{display:flex;flex-direction:row;clear:left;flex-wrap:wrap;width:100%;box-sizing:border-box}.mw-parser-output .tmulti .tsingle{margin:1px;float:left}.mw-parser-output .tmulti .theader{clear:both;font-weight:bold;text-align:center;align-self:center;background-color:transparent;width:100%}.mw-parser-output .tmulti .thumbcaption{text-align:left;background-color:transparent}.mw-parser-output .tmulti .thumbcaption-center{text-align:center;background-color:transparent}.mw-parser-output .tmulti .text-align-left{text-align:left}.mw-parser-output .tmulti .text-align-right{text-align:right}.mw-parser-output .tmulti .text-align-center{text-align:center}@media all and (max-width:720px){.mw-parser-output .tmulti .thumbinner{width:100%!important;box-sizing:border-box;max-width:none!important;align-items:center}.mw-parser-output .tmulti .trow{justify-content:center}.mw-parser-output .tmulti .tsingle{float:none!important;max-width:100%!important;box-sizing:border-box;text-align:center}.mw-parser-output .tmulti .thumbcaption{text-align:center}}</style><div class="thumb tmulti tright"><div class="thumbinner" style="width:608px;max-width:608px"><div class="trow"><div class="tsingle" style="width:252px;max-width:252px"><div class="thumbimage"><figure-inline><img src="../I/m/Prerapamycin_skeletal.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Prerapamycin_skeletal.svg.png" data-file-width="307" data-file-height="289" data-file-type="drawing" height="235" width="250"></figure-inline></div><div class="thumbcaption">Figure 2: Prerapamycin, unbound product of PKS and NRPS</div></div><div class="tsingle" style="width:352px;max-width:352px"><div class="thumbimage"><figure-inline><img src="../I/m/Prerapamycin_to_rapamycin.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Prerapamycin_to_rapamycin.svg.png" data-file-width="422" data-file-height="307" data-file-type="drawing" height="255" width="350"></figure-inline></div><div class="thumbcaption">Figure 3: Sequence of "tailoring" steps, which convert unbound prerapamycin into rapamycin</div></div></div></div></div>
<div class="thumb tright"><div class="thumbinner" style="width:222px"><img src="../I/m/Picolinic_acid_biosynthesis.png" tppabs="https://ptable.com/wiki/compounds/I/m/Picolinic_acid_biosynthesis.png" data-file-width="3155" data-file-height="1527" data-file-type="bitmap" height="106" width="220"><div class="thumbcaption" style="text-align: left">Figure 4: Proposed mechanism of lysine cyclodeaminase conversion of L-lysine to L-pipecolic acid</div></div></div>
<p>The core macrocycle, prerapamycin (figure 2), is then modified (figure 3) by an additional five enzymes, which lead to the final product, rapamycin. First, the core macrocycle is modified by RapI, SAM-dependent O-methyltransferase (MTase), which O-methylates at C39. Next, a carbonyl is installed at C9 by RapJ, a cytochrome P-450 monooxygenases (P-450). Then, RapM, another MTase, O-methylates at C16. Finally, RapN, another P-450, installs a hydroxyl at C27 immediately followed by O-methylation by Rap Q, a distinct MTase, at C27 to yield rapamycin.<span class="mw-ref" id="cite_ref-Rapamycin_genes_41-0"><a href="#cite_note-Rapamycin_genes-41" style="counter-reset: mw-Ref 41;"><span class="mw-reflink-text">[41]</span></a></span></p>

<p>The biosynthetic genes responsible for rapamycin synthesis have been identified. As expected, three extremely large open reading frames (ORF's) designated as <i>rapA</i>, <i>rapB</i>, and <i>rapC</i> encode for three extremely large and complex multienzymes, RapA, RapB, and RapC, respectively.<span class="mw-ref" id="cite_ref-Rapamycin_domains_and_primary_genes_39-1"><a href="#cite_note-Rapamycin_domains_and_primary_genes-39" style="counter-reset: mw-Ref 39;"><span class="mw-reflink-text">[39]</span></a></span> The gene <i>rapL</i> has been established to code for a <a href="Nicotinamide_adenine_dinucleotide.htm" tppabs="https://ptable.com/wiki/compounds/A/NAD%2B" title="NAD+" class="mw-redirect">NAD+</a>-dependent <a href="Lysine.htm" tppabs="https://ptable.com/wiki/compounds/A/Lysine" title="Lysine">lysine</a> cycloamidase, which converts L-<a href="Lysine.htm" tppabs="https://ptable.com/wiki/compounds/A/Lysine" title="Lysine">lysine</a> to L-<a href="Pipecolic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Pipecolic_acid" title="Pipecolic acid">pipecolic acid</a> (figure 4) for incorporation at the end of the polyketide.<span class="mw-ref" id="cite_ref-rapamycin_report_42-0"><a href="#cite_note-rapamycin_report-42" style="counter-reset: mw-Ref 42;"><span class="mw-reflink-text">[42]</span></a></span><span class="mw-ref" id="cite_ref-43"><a href="#cite_note-43" style="counter-reset: mw-Ref 43;"><span class="mw-reflink-text">[43]</span></a></span>  The gene <i>rapP</i>, which is embedded between the PKS genes and translationally coupled to <i>rapC</i>, encodes for an additional enzyme, an NPRS responsible for incorporating L-pipecolic acid, chain termination and cyclization of prerapamycin. In addition, genes <i>rapI</i>, <i>rapJ</i>, <i>rapM</i>, <i>rapN</i>, <i>rapO</i>, and <i>rapQ</i> have been identified as coding for tailoring enzymes that modify the macrocyclic core to give rapamycin (figure 3). Finally, <i>rapG</i> and <i>rapH</i> have been identified to code for enzymes that have a positive regulatory role in the preparation of rapamycin through the control of rapamycin PKS gene expression.<span class="mw-ref" id="cite_ref-rapG_rapH_44-0"><a href="#cite_note-rapG_rapH-44" style="counter-reset: mw-Ref 44;"><span class="mw-reflink-text">[44]</span></a></span>
Biosynthesis of this 31-membered macrocycle begins as the loading domain is primed with the starter unit, 4,5-dihydroxocyclohex-1-ene-carboxylic acid, which is derived from the shikimate pathway.<span class="mw-ref" id="cite_ref-Rapamycin_domains_and_primary_genes_39-2"><a href="#cite_note-Rapamycin_domains_and_primary_genes-39" style="counter-reset: mw-Ref 39;"><span class="mw-reflink-text">[39]</span></a></span> Note that the <a href="Cyclohexane.htm" tppabs="https://ptable.com/wiki/compounds/A/Cyclohexane" title="Cyclohexane">cyclohexane</a> ring of the starting unit is reduced during the transfer to module 1. The starting unit is then modified by a series of Claisen condensations with <a href="Malonate.htm" tppabs="https://ptable.com/wiki/compounds/A/Malonyl" title="Malonyl" class="mw-redirect">malonyl</a> or methylmalonyl substrates, which are attached to an acyl carrier protein (ACP) and extend the polyketide by two carbons each. After each successive condensation, the growing polyketide is further modified according to enzymatic domains that are present to reduce and dehydrate it, thereby introducing the diversity of functionalities observed in rapamycin (figure 1). Once the linear polyketide is complete, L-pipecolic acid, which is synthesized by a lysine cycloamidase from an L-lysine, is added to the terminal end of the polyketide by an NRPS. Then, the NSPS cyclizes the polyketide, giving prerapamycin, the first enzyme-free product. The macrocyclic core is then customized by a series of post-PKS enzymes through methylations by MTases and oxidations by P-450s to yield rapamycin.</p>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Research">Research</h2></summary>
    
<span>

</span>
<div class="thumb tright"><div class="thumbinner" style="width:302px"><img src="../I/m/Rapamycin_plaque_on_Easter_Island.JPG" tppabs="https://ptable.com/wiki/compounds/I/m/Rapamycin_plaque_on_Easter_Island.JPG" data-file-width="1536" data-file-height="1024" data-file-type="bitmap" height="200" width="300"><div class="thumbcaption" style="text-align: left">A plaque, written in Portuguese, commemorating the discovery of sirolimus on Easter Island, near Rano Kau</div></div></div>


    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Cancer">Cancer</h3></summary>
    
<p>The antiproliferative effects of sirolimus may have a role in treating cancer. When dosed appropriately, sirolimus can enhance the immune response to tumor targeting<span class="mw-ref" id="cite_ref-45"><a href="#cite_note-45" style="counter-reset: mw-Ref 45;"><span class="mw-reflink-text">[45]</span></a></span> or otherwise promote tumor regression in clinical trials.<span class="mw-ref" id="cite_ref-46"><a href="#cite_note-46" style="counter-reset: mw-Ref 46;"><span class="mw-reflink-text">[46]</span></a></span> Sirolimus seems to lower the cancer risk in some transplant patients.<span class="mw-ref" id="cite_ref-Law2005_47-0"><a href="#cite_note-Law2005-47" style="counter-reset: mw-Ref 47;"><span class="mw-reflink-text">[47]</span></a></span></p>

<p>Sirolimus was shown to inhibit the progression of dermal Kaposi's sarcoma in patients with renal transplants.  Other mTOR inhibitors, such as <a href="Temsirolimus.htm" tppabs="https://ptable.com/wiki/compounds/A/Temsirolimus" title="Temsirolimus">temsirolimus</a> (CCI-779) or <a href="Everolimus.htm" tppabs="https://ptable.com/wiki/compounds/A/Everolimus" title="Everolimus">everolimus</a> (RAD001), are being tested for use in cancers such as glioblastoma multiforme and mantle cell lymphoma. However, these drugs have a higher rate of fatal adverse events in cancer patients than control drugs.<span class="mw-ref" id="cite_ref-48"><a href="#cite_note-48" style="counter-reset: mw-Ref 48;"><span class="mw-reflink-text">[48]</span></a></span></p>

<p>A combination therapy of <a href="Doxorubicin.htm" tppabs="https://ptable.com/wiki/compounds/A/Doxorubicin" title="Doxorubicin">doxorubicin</a> and sirolimus has been shown to drive AKT-positive lymphomas into remission in mice. Akt signalling promotes cell survival in Akt-positive lymphomas and acts to prevent the cytotoxic effects of chemotherapy drugs, such as <a href="Doxorubicin.htm" tppabs="https://ptable.com/wiki/compounds/A/Doxorubicin" title="Doxorubicin">doxorubicin</a> or <a href="Cyclophosphamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Cyclophosphamide" title="Cyclophosphamide">cyclophosphamide</a>. Sirolimus blocks Akt signalling and the cells lose their resistance to the chemotherapy. Bcl-2-positive lymphomas were completely resistant to the therapy; eIF4E-expressing lymphomas are not sensitive to sirolimus.<span class="mw-ref" id="cite_ref-49"><a href="#cite_note-49" style="counter-reset: mw-Ref 49;"><span class="mw-reflink-text">[49]</span></a></span><span class="mw-ref" id="cite_ref-Chan_50-0"><a href="#cite_note-Chan-50" style="counter-reset: mw-Ref 50;"><span class="mw-reflink-text">[50]</span></a></span><span class="mw-ref" id="cite_ref-ScienceDaily_51-0"><a href="#cite_note-ScienceDaily-51" style="counter-reset: mw-Ref 51;"><span class="mw-reflink-text">[51]</span></a></span><span class="mw-ref" id="cite_ref-SignalingGateway_52-0"><a href="#cite_note-SignalingGateway-52" style="counter-reset: mw-Ref 52;"><span class="mw-reflink-text">[52]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Tuberous_sclerosis_complex">Tuberous sclerosis complex</h3></summary>
    
<p>Sirolimus also shows promise in treating tuberous sclerosis complex (TSC), a congenital disorder that leaves sufferers prone to benign tumor growth in the brain, heart, kidneys, skin, and other organs. After several studies conclusively linked mTOR inhibitors to remission in TSC tumors, specifically subependymal giant-cell astrocytomas in children and angiomyolipomas in adults, many US doctors began prescribing sirolimus (Wyeth's Rapamune) and <a href="Everolimus.htm" tppabs="https://ptable.com/wiki/compounds/A/Everolimus" title="Everolimus">everolimus</a> (Novartis's RAD001) to TSC patients off-label. Numerous clinical trials using both rapamycin analogs, involving both children and adults with TSC, are underway in the United States.<span class="mw-ref" id="cite_ref-53"><a href="#cite_note-53" style="counter-reset: mw-Ref 53;"><span class="mw-reflink-text">[53]</span></a></span></p>

<p>Most studies thus far have noted that tumors often regrew when treatment stopped.</p>

<p>Facial angiofibromas occur in 80% of patients with TSC, and the condition is very disfiguring. A retrospective review of English-language medical publications reporting on topical sirolimus treatment of facial angiofibromas found sixteen separate studies with positive patient outcomes after using the drug. The reports involved a total of 84 patients, and improvement was observed in 94% of subjects, especially if treatment began during the early stages of the disease. Sirolimus treatment was applied in several different formulations (ointment, gel, solution, and cream), ranging from 0.003 to 1% concentrations. Reported adverse effects included one case of perioral dermatitis, one case of cephalea, and four cases of irritation.<span class="mw-ref" id="cite_ref-54"><a href="#cite_note-54" style="counter-reset: mw-Ref 54;"><span class="mw-reflink-text">[54]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Effects_on_longevity">Effects on longevity</h3></summary>
    
<p>mTOR, specifically mTOR1, was first shown to be important in aging in 2003, in a study on worms; sirolimus was shown to inhibit and slow aging in worms, yeast, and flies, and then to improve the condition of mouse models of various diseases of aging.<span class="mw-ref" id="cite_ref-Apelo2016rev_55-0"><a href="#cite_note-Apelo2016rev-55" style="counter-reset: mw-Ref 55;"><span class="mw-reflink-text">[55]</span></a></span>  Sirolimus was first shown to extend lifespan in wild-type mice in a study published by NIH investigators in 2009; the studies have been replicated in mice of many different genetic backgrounds.<span class="mw-ref" id="cite_ref-Apelo2016rev_55-1"><a href="#cite_note-Apelo2016rev-55" style="counter-reset: mw-Ref 55;"><span class="mw-reflink-text">[55]</span></a></span> The results are further supported by the finding that genetically modified mice with impaired mTOR1 signalling live longer.<span class="mw-ref" id="cite_ref-Apelo2016rev_55-2"><a href="#cite_note-Apelo2016rev-55" style="counter-reset: mw-Ref 55;"><span class="mw-reflink-text">[55]</span></a></span> The known adverse effects caused by sirolimus and marketed analogs at the doses used in transplant regimens, especially the increased risk of infection due to immunosuppression, as well as dose-dependent metabolic impairment, make it unlikely that chronic, long-term treatment with sirolimus could become a widely used anti-aging agent.<span class="mw-ref" id="cite_ref-Apelo2016rev_55-3"><a href="#cite_note-Apelo2016rev-55" style="counter-reset: mw-Ref 55;"><span class="mw-reflink-text">[55]</span></a></span></p>

<p>Rapamycin has complex effects on the immune system—while IL-12 goes up and IL-10 decreases, which suggests an immunostimulatory response, TNF and IL-6 are decreased, which suggests an immunosuppressive response. The duration of the inhibition and the exact extent to which mTORC1 and mTORC2 are inhibited play a role, but are not yet well understood.<span class="mw-ref" id="cite_ref-56"><a href="#cite_note-56" style="counter-reset: mw-Ref 56;"><span class="mw-reflink-text">[56]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Lupus">Lupus</h3></summary>
    
<p>As of 2016 studies in cells, animals, and humans have suggested that mTOR activation as process underlying systemic lupus erythematosus and that inhibiting mTOR with rapamycin may be a disease-modifying treatment.<span class="mw-ref" id="cite_ref-Oaks2016rev_57-0"><a href="#cite_note-Oaks2016rev-57" style="counter-reset: mw-Ref 57;"><span class="mw-reflink-text">[57]</span></a></span> As of 2016 rapamycin had been tested in small clinical trials in people with lupus.<span class="mw-ref" id="cite_ref-Oaks2016rev_57-1"><a href="#cite_note-Oaks2016rev-57" style="counter-reset: mw-Ref 57;"><span class="mw-reflink-text">[57]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Lymphatic_malformation">Lymphatic malformation</h3></summary>
    
<p>Lymphatic malformation is either a superficial, deep or mixed growth of lymphatic vessels. Treatment is limited to removal or destruction, however, the rate of recurrence is high. García M et al.<span class="mw-ref" id="cite_ref-58"><a href="#cite_note-58" style="counter-reset: mw-Ref 58;"><span class="mw-reflink-text">[58]</span></a></span> made a topical formulation of rapamycin, and conducted a small case series, involving 11 patients with superficial lymphatic malformations. The clinical appearance improved in all 11, and symptoms improved in 9 of the 11. The average follow-up time was 16.1 months, indicating that topical rapamycin, ranging from .4-1.0% is promising for management of superficial lymphatic malformations.</p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Applications_in_biology_research">Applications in biology research</h3></summary>
    
<p>Rapamycin is used in biology research as an agent for chemically induced dimerization.<span class="mw-ref" id="cite_ref-59"><a href="#cite_note-59" style="counter-reset: mw-Ref 59;"><span class="mw-reflink-text">[59]</span></a></span> In this application, rapamycin is added to cells expressing two fusion constructs, one of which contains the rapamycin-binding FRB domain from mTOR and the other of which contains an FKBP domain. Each fusion protein also contains additional domains that are brought into proximity when rapamycin induces binding of FRB and FKBP. In this way, rapamycin can be used to control and study protein localization and interactions.</p>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="References">References</h2></summary>
    
<div class="reflist " style=" list-style-type: decimal;">
<div class="mw-references-wrap mw-references-columns"><ol class="mw-references references"><li id="cite_note-1"> <span id="mw-reference-text-cite_note-1" class="mw-reference-text"><cite id="CITEREFBuck2006" class="citation journal cs1">Buck ML (2006). <a href="javascript:if(confirm('http://www.medscape.com/viewarticle/524753_4  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.medscape.com/viewarticle/524753_4'" tppabs="http://www.medscape.com/viewarticle/524753_4" class="external text external">"Immunosuppression With Sirolimus After Solid Organ Transplantation in Children"</a>. <i>Pediatric Pharmacotherapy</i>. <b>12</b> (2).</cite></span></li><li id="cite_note-Pubchem_Rapamycin-2"> <span id="mw-reference-text-cite_note-Pubchem_Rapamycin-2" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://pubchem.ncbi.nlm.nih.gov/compound/5284616  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubchem.ncbi.nlm.nih.gov/compound/5284616'" tppabs="https://pubchem.ncbi.nlm.nih.gov/compound/5284616" class="external text external">"Rapamycin"</a>. <i>PubChem Compound</i>. National Center for Biotechnology Information<span class="reference-accessdate">. Retrieved <span class="nowrap">1 August</span> 2016</span>.</cite></span></li><li id="cite_note-3"> <span id="mw-reference-text-cite_note-3" class="mw-reference-text"><cite id="CITEREFSimamoraAlvarezYalkowsky2001" class="citation journal cs1">Simamora P, Alvarez JM, Yalkowsky SH (February 2001). "Solubilization of rapamycin". <i>International Journal of Pharmaceutics</i>. <b>213</b> (1–2): 25–9. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fs0378-5173%2800%2900617-7  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fs0378-5173%2800%2900617-7'" tppabs="https://doi.org/10.1016%2Fs0378-5173%2800%2900617-7" class="external text external">10.1016/s0378-5173(00)00617-7</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/11165091  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/11165091'" tppabs="https://pubmed.ncbi.nlm.nih.gov/11165091" class="external text external">11165091</a>.</cite></span></li><li id="cite_note-Rapamune_Rx_info-4"> <span id="mw-reference-text-cite_note-Rapamune_Rx_info-4" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021083s058,021110s075lbl.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021083s058,021110s075lbl.pdf'" tppabs="http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021083s058,021110s075lbl.pdf" class="external text external">"Rapamune Prescribing Information"</a> <span class="cs1-format">(PDF)</span>. <i>United States Food and Drug Administration</i>. Wyeth Pharmaceuticals, Inc. May 2015<span class="reference-accessdate">. Retrieved <span class="nowrap">28 May</span> 2016</span>.</cite></span></li><li id="cite_note-Vezi-5"> <span id="mw-reference-text-cite_note-Vezi-5" class="mw-reference-text"><cite id="CITEREFVézinaKudelskiSehgal1975" class="citation journal cs1">Vézina C, Kudelski A, Sehgal SN (October 1975). <a href="javascript:if(confirm('https://doi.org/10.7164/antibiotics.28.721  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.7164/antibiotics.28.721'" tppabs="https://doi.org/10.7164/antibiotics.28.721" class="external text external">"Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle"</a>. <i>The Journal of Antibiotics</i>. <b>28</b> (10): 721–6. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.7164%2Fantibiotics.28.721  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.7164%2Fantibiotics.28.721'" tppabs="https://doi.org/10.7164%2Fantibiotics.28.721" class="external text external">10.7164/antibiotics.28.721</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/1102508  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/1102508'" tppabs="https://pubmed.ncbi.nlm.nih.gov/1102508" class="external text external">1102508</a>.</cite></span></li><li id="cite_note-Cypher-6"> <span id="mw-reference-text-cite_note-Cypher-6" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://web.archive.org/web/20030427143416/http://www.cypherusa.com/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20030427143416/http://www.cypherusa.com/'" tppabs="https://web.archive.org/web/20030427143416/http://www.cypherusa.com/" class="external text external">"Cypher Sirolimus-eluting Coronary Stent"</a>. Cypher Stent. Archived from <a href="javascript:if(confirm('http://www.cypherusa.com/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.cypherusa.com/'" tppabs="http://www.cypherusa.com/" class="external text external">the original</a> on 27 April 2003<span class="reference-accessdate">. Retrieved <span class="nowrap">1 April</span> 2008</span>.</cite></span></li><li id="cite_note-Mukherjee_2009-7"> <span id="mw-reference-text-cite_note-Mukherjee_2009-7" class="mw-reference-text"><cite id="CITEREFMukherjeeMukherjee2009" class="citation journal cs1">Mukherjee S, Mukherjee U (1 January 2009). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2809333  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2809333'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2809333" class="external text external">"A comprehensive review of immunosuppression used for liver transplantation"</a>. <i>Journal of Transplantation</i>. <b>2009</b>: 701464. doi:<a href="javascript:if(confirm('https://doi.org/10.1155%2F2009%2F701464  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1155%2F2009%2F701464'" tppabs="https://doi.org/10.1155%2F2009%2F701464" class="external text external">10.1155/2009/701464</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2809333  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2809333'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2809333" class="external text external">2809333</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/20130772  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/20130772'" tppabs="https://pubmed.ncbi.nlm.nih.gov/20130772" class="external text external">20130772</a>.</cite></span></li><li id="cite_note-8"> <span id="mw-reference-text-cite_note-8" class="mw-reference-text"><cite id="CITEREFSeto2012" class="citation journal cs1">Seto B (November 2012). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3561035  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3561035'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3561035" class="external text external">"Rapamycin and mTOR: a serendipitous discovery and implications for breast cancer"</a>. <i>Clinical and Translational Medicine</i>. <b>1</b> (1): 29. doi:<a href="javascript:if(confirm('https://doi.org/10.1186%2F2001-1326-1-29  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1186%2F2001-1326-1-29'" tppabs="https://doi.org/10.1186%2F2001-1326-1-29" class="external text external">10.1186/2001-1326-1-29</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3561035  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3561035'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3561035" class="external text external">3561035</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/23369283  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/23369283'" tppabs="https://pubmed.ncbi.nlm.nih.gov/23369283" class="external text external">23369283</a>.</cite></span></li><li id="cite_note-RapamycinOrigin-9"> <span id="mw-reference-text-cite_note-RapamycinOrigin-9" class="mw-reference-text"><cite id="CITEREFPritchard2005" class="citation journal cs1">Pritchard DI (May 2005). "Sourcing a chemical succession for cyclosporin from parasites and human pathogens". <i>Drug Discovery Today</i>. <b>10</b> (10): 688–91. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2FS1359-6446%2805%2903395-7  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2FS1359-6446%2805%2903395-7'" tppabs="https://doi.org/10.1016%2FS1359-6446%2805%2903395-7" class="external text external">10.1016/S1359-6446(05)03395-7</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/15896681  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/15896681'" tppabs="https://pubmed.ncbi.nlm.nih.gov/15896681" class="external text external">15896681</a>.</cite></span></li><li id="cite_note-10"> <span id="mw-reference-text-cite_note-10" class="mw-reference-text"><cite id="CITEREFLiCorey2013" class="citation book cs1">Li JJ, Corey EJ (3 April 2013). <a href="javascript:if(confirm('https://books.google.com/books?id=mIyxO5cLEAcC  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=mIyxO5cLEAcC'" tppabs="https://books.google.com/books?id=mIyxO5cLEAcC" class="external text external"><i>Drug Discovery: Practices, Processes, and Perspectives</i></a>. John Wiley &amp; Sons. ISBN<span>&nbsp;</span><bdi>978-1-118-35446-9</bdi>.</cite></span></li><li id="cite_note-11"> <span id="mw-reference-text-cite_note-11" class="mw-reference-text"><cite id="CITEREFKoprowski2012" class="citation book cs1">Koprowski G (7 February 2012). <a href="javascript:if(confirm('https://books.google.com/books?id=CVloCgAAQBAJ  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=CVloCgAAQBAJ'" tppabs="https://books.google.com/books?id=CVloCgAAQBAJ" class="external text external"><i>Nanotechnology in Medicine: Emerging Applications</i></a>. Momentum Press. ISBN<span>&nbsp;</span><bdi>978-1-60650-250-1</bdi>.</cite></span></li><li id="cite_note-12"> <span id="mw-reference-text-cite_note-12" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm165731.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm165731.htm'" tppabs="https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm165731.htm" class="external text external">"Sirolimus (marketed as Rapamune) Safety"</a>. <i>FDA.gov</i>. U.S. Food and Drug Administration. 11 June 2009<span class="reference-accessdate">. Retrieved <span class="nowrap">1 August</span> 2016</span>.</cite></span></li><li id="cite_note-FDA_2015-13"> <span id="mw-reference-text-cite_note-FDA_2015-13" class="mw-reference-text"><cite id="CITEREFPahon2015" class="citation web cs1">Pahon E (28 May 2015). <a href="javascript:if(confirm('https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm448523.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm448523.htm'" tppabs="https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm448523.htm" class="external text external">"FDA approves Rapamune to treat LAM, a very rare lung disease"</a>. <i>FDA.gov</i>. U.S. Food and Drug Administration<span class="reference-accessdate">. Retrieved <span class="nowrap">1 August</span> 2016</span>.</cite></span></li><li id="cite_note-Shuchman-14"> <span id="mw-reference-text-cite_note-Shuchman-14" class="mw-reference-text"><cite id="CITEREFShuchman2006" class="citation journal cs1">Shuchman M (November 2006). "Trading restenosis for thrombosis? New questions about drug-eluting stents". <i>The New England Journal of Medicine</i>. <b>355</b> (19): 1949–52. doi:<a href="javascript:if(confirm('https://doi.org/10.1056%2FNEJMp068234  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1056%2FNEJMp068234'" tppabs="https://doi.org/10.1056%2FNEJMp068234" class="external text external">10.1056/NEJMp068234</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/17093244  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/17093244'" tppabs="https://pubmed.ncbi.nlm.nih.gov/17093244" class="external text external">17093244</a>.</cite></span></li><li id="cite_note-15"> <span id="mw-reference-text-cite_note-15" class="mw-reference-text"><a href="javascript:if(confirm('http://www.childrenshospital.org/conditions-and-treatments/conditions/v/venous-malformation/treatments  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.childrenshospital.org/conditions-and-treatments/conditions/v/venous-malformation/treatments'" tppabs="http://www.childrenshospital.org/conditions-and-treatments/conditions/v/venous-malformation/treatments" class="external free external">http://www.childrenshospital.org/conditions-and-treatments/conditions/v/venous-malformation/treatments</a></span></li><li id="cite_note-16"> <span id="mw-reference-text-cite_note-16" class="mw-reference-text">Dekeuleneer, Valérie, et al. "Theranostic Advances in Vascular Malformations." Journal of Investigative Dermatology 140.4 (2020): 756-763.</span></li><li id="cite_note-17"> <span id="mw-reference-text-cite_note-17" class="mw-reference-text">Lee, Byung-Boong. "Sirolimus in the treatment of vascular anomalies." <a href="javascript:if(confirm('https://www.jvascsurg.org/article/S0741-5214(19)32236-0/fulltext  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.jvascsurg.org/article/S0741-5214(19)32236-0/fulltext'" tppabs="https://www.jvascsurg.org/article/S0741-5214(19)32236-0/fulltext" class="external free external">https://www.jvascsurg.org/article/S0741-5214(19)32236-0/fulltext</a>, Journal of Vascular Surgery 71.1 (2020): 328.</span></li><li id="cite_note-18"> <span id="mw-reference-text-cite_note-18" class="mw-reference-text"><cite id="CITEREFLammingYeKatajistoGoncalves2012" class="citation journal cs1">Lamming, Dudley W.; Ye, Lan; Katajisto, Pekka; Goncalves, Marcus D.; Saitoh, Maki; Stevens, Deanna M.; Davis, James G.; Salmon, Adam B.; Richardson, Arlan (30 March 2012). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3324089  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3324089'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3324089" class="external text external">"Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity"</a>. <i>Science</i>. <b>335</b> (6076): 1638–1643. Bibcode:<a href="javascript:if(confirm('https://ui.adsabs.harvard.edu/abs/2012Sci...335.1638L  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://ui.adsabs.harvard.edu/abs/2012Sci...335.1638L'" tppabs="https://ui.adsabs.harvard.edu/abs/2012Sci...335.1638L" class="external text external">2012Sci...335.1638L</a>. doi:<a href="javascript:if(confirm('https://doi.org/10.1126%2Fscience.1215135  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1126%2Fscience.1215135'" tppabs="https://doi.org/10.1126%2Fscience.1215135" class="external text external">10.1126/science.1215135</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/1095-9203  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/1095-9203'" tppabs="https://www.worldcat.org/issn/1095-9203" class="external text external">1095-9203</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3324089  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3324089'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3324089" class="external text external">3324089</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/22461615  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/22461615'" tppabs="https://pubmed.ncbi.nlm.nih.gov/22461615" class="external text external">22461615</a>.</cite></span></li><li id="cite_note-19"> <span id="mw-reference-text-cite_note-19" class="mw-reference-text"><cite class="citation journal cs1">Lamming DW, Ye L, Katajisto P, Goncalves MD, Saitoh M, Stevens DM, Davis JG, Salmon AB, Richardson A, Ahima RS, Guertin DA, Sabatini DM, Baur JA (March 2012). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3324089  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3324089'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3324089" class="external text external">"Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity"</a>. <i>Science</i>. <b>335</b> (6076): 1638–43. Bibcode:<a href="javascript:if(confirm('https://ui.adsabs.harvard.edu/abs/2012Sci...335.1638L  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://ui.adsabs.harvard.edu/abs/2012Sci...335.1638L'" tppabs="https://ui.adsabs.harvard.edu/abs/2012Sci...335.1638L" class="external text external">2012Sci...335.1638L</a>. doi:<a href="javascript:if(confirm('https://doi.org/10.1126%2Fscience.1215135  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1126%2Fscience.1215135'" tppabs="https://doi.org/10.1126%2Fscience.1215135" class="external text external">10.1126/science.1215135</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3324089  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3324089'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3324089" class="external text external">3324089</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/22461615  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/22461615'" tppabs="https://pubmed.ncbi.nlm.nih.gov/22461615" class="external text external">22461615</a>.</cite></span></li><li id="cite_note-20"> <span id="mw-reference-text-cite_note-20" class="mw-reference-text"><cite id="CITEREFJohnstonRoseWebsterGill2008" class="citation journal cs1">Johnston O, Rose CL, Webster AC, Gill JS (July 2008). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2440303  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2440303'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2440303" class="external text external">"Sirolimus is associated with new-onset diabetes in kidney transplant recipients"</a>. <i>Journal of the American Society of Nephrology</i>. <b>19</b> (7): 1411–8. doi:<a href="javascript:if(confirm('https://doi.org/10.1681%2FASN.2007111202  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1681%2FASN.2007111202'" tppabs="https://doi.org/10.1681%2FASN.2007111202" class="external text external">10.1681/ASN.2007111202</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2440303  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2440303'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2440303" class="external text external">2440303</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/18385422  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/18385422'" tppabs="https://pubmed.ncbi.nlm.nih.gov/18385422" class="external text external">18385422</a>.</cite></span></li><li id="cite_note-21"> <span id="mw-reference-text-cite_note-21" class="mw-reference-text"><cite id="CITEREFArriola_ApeloNeumanBaarSyed2016" class="citation journal cs1">Arriola Apelo SI, Neuman JC, Baar EL, Syed FA, Cummings NE, Brar HK, Pumper CP, Kimple ME, Lamming DW (February 2016). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4717280  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4717280'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4717280" class="external text external">"Alternative rapamycin treatment regimens mitigate the impact of rapamycin on glucose homeostasis and the immune system"</a>. <i>Aging Cell</i>. <b>15</b> (1): 28–38. doi:<a href="javascript:if(confirm('https://doi.org/10.1111%2Facel.12405  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1111%2Facel.12405'" tppabs="https://doi.org/10.1111%2Facel.12405" class="external text external">10.1111/acel.12405</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4717280  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4717280'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4717280" class="external text external">4717280</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/26463117  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/26463117'" tppabs="https://pubmed.ncbi.nlm.nih.gov/26463117" class="external text external">26463117</a>.</cite></span></li><li id="cite_note-ReferenceA-22"> <span id="mw-reference-text-cite_note-ReferenceA-22" class="mw-reference-text"><cite id="CITEREFChhajedDickenmannBubendorfMayr2006" class="citation journal cs1">Chhajed PN, Dickenmann M, Bubendorf L, Mayr M, Steiger J, Tamm M (2006). "Patterns of pulmonary complications associated with sirolimus". <i>Respiration</i>. <b>73</b> (3): 367–74. doi:<a href="javascript:if(confirm('https://doi.org/10.1159%2F000087945  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1159%2F000087945'" tppabs="https://doi.org/10.1159%2F000087945" class="external text external">10.1159/000087945</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/16127266  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/16127266'" tppabs="https://pubmed.ncbi.nlm.nih.gov/16127266" class="external text external">16127266</a>.</cite></span></li><li id="cite_note-23"> <span id="mw-reference-text-cite_note-23" class="mw-reference-text"><cite id="CITEREFMorelonSternIsraël-BietCorreas2001" class="citation journal cs1">Morelon E, Stern M, Israël-Biet D, Correas JM, Danel C, Mamzer-Bruneel MF, Peraldi MN, Kreis H (September 2001). "Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients". <i>Transplantation</i>. <b>72</b> (5): 787–90. doi:<a href="javascript:if(confirm('https://doi.org/10.1097%2F00007890-200109150-00008  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1097%2F00007890-200109150-00008'" tppabs="https://doi.org/10.1097%2F00007890-200109150-00008" class="external text external">10.1097/00007890-200109150-00008</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/11571438  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/11571438'" tppabs="https://pubmed.ncbi.nlm.nih.gov/11571438" class="external text external">11571438</a>.</cite></span></li><li id="cite_note-24"> <span id="mw-reference-text-cite_note-24" class="mw-reference-text"><cite id="CITEREFFilipponeCarsonBeckfordJaffe2011" class="citation journal cs1">Filippone EJ, Carson JM, Beckford RA, Jaffe BC, Newman E, Awsare BK, Doria C, Farber JL (September 2011). <a href="javascript:if(confirm('https://jdc.jefferson.edu/cgi/viewcontent.cgi?article=1087&context=medfp  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://jdc.jefferson.edu/cgi/viewcontent.cgi?article=1087&context=medfp'" tppabs="https://jdc.jefferson.edu/cgi/viewcontent.cgi?article=1087&context=medfp" class="external text external">"Sirolimus-induced pneumonitis complicated by pentamidine-induced phospholipidosis in a renal transplant recipient: a case report"</a>. <i>Transplantation Proceedings</i>. <b>43</b> (7): 2792–7. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.transproceed.2011.06.060  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.transproceed.2011.06.060'" tppabs="https://doi.org/10.1016%2Fj.transproceed.2011.06.060" class="external text external">10.1016/j.transproceed.2011.06.060</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/21911165  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/21911165'" tppabs="https://pubmed.ncbi.nlm.nih.gov/21911165" class="external text external">21911165</a>.</cite></span></li><li id="cite_note-25"> <span id="mw-reference-text-cite_note-25" class="mw-reference-text"><cite id="CITEREFPhamPhamDanovitchRoss2004" class="citation journal cs1">Pham PT, Pham PC, Danovitch GM, Ross DJ, Gritsch HA, Kendrick EA, Singer J, Shah T, Wilkinson AH (April 2004). "Sirolimus-associated pulmonary toxicity". <i>Transplantation</i>. <b>77</b> (8): 1215–20. doi:<a href="javascript:if(confirm('https://doi.org/10.1097%2F01.TP.0000118413.92211.B6  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1097%2F01.TP.0000118413.92211.B6'" tppabs="https://doi.org/10.1097%2F01.TP.0000118413.92211.B6" class="external text external">10.1097/01.TP.0000118413.92211.B6</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/15114088  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/15114088'" tppabs="https://pubmed.ncbi.nlm.nih.gov/15114088" class="external text external">15114088</a>.</cite></span></li><li id="cite_note-26"> <span id="mw-reference-text-cite_note-26" class="mw-reference-text"><cite id="CITEREFMingosKane2005" class="citation journal cs1">Mingos MA, Kane GC (December 2005). <a href="javascript:if(confirm('http://www.rcjournal.com/contents/12.05/12.05.1659.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.rcjournal.com/contents/12.05/12.05.1659.pdf'" tppabs="http://www.rcjournal.com/contents/12.05/12.05.1659.pdf" class="external text external">"Sirolimus-induced interstitial pneumonitis in a renal transplant patient"</a> <span class="cs1-format">(PDF)</span>. <i>Respiratory Care</i>. <b>50</b> (12): 1659–61. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/16318648  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/16318648'" tppabs="https://pubmed.ncbi.nlm.nih.gov/16318648" class="external text external">16318648</a>.</cite></span></li><li id="cite_note-27"> <span id="mw-reference-text-cite_note-27" class="mw-reference-text"><cite id="CITEREFDasShoemakerSubramanianJohnsrude2007" class="citation journal cs1">Das BB, Shoemaker L, Subramanian S, Johnsrude C, Recto M, Austin EH (March 2007). "Acute sirolimus pulmonary toxicity in an infant heart transplant recipient: case report and literature review". <i>The Journal of Heart and Lung Transplantation</i>. <b>26</b> (3): 296–8. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.healun.2006.12.004  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.healun.2006.12.004'" tppabs="https://doi.org/10.1016%2Fj.healun.2006.12.004" class="external text external">10.1016/j.healun.2006.12.004</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/17346635  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/17346635'" tppabs="https://pubmed.ncbi.nlm.nih.gov/17346635" class="external text external">17346635</a>.</cite>
</span></li><li id="cite_note-28"> <span id="mw-reference-text-cite_note-28" class="mw-reference-text"><cite id="CITEREFDelgadoTorresJosé_Ruiz-CanoSánchez2006" class="citation journal cs1">Delgado JF, Torres J, José Ruiz-Cano M, Sánchez V, Escribano P, Borruel S, María Cortina J, de la Calzada CS (September 2006). "Sirolimus-associated interstitial pneumonitis in 3 heart transplant recipients". <i>The Journal of Heart and Lung Transplantation</i>. <b>25</b> (9): 1171–4. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.healun.2006.05.013  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.healun.2006.05.013'" tppabs="https://doi.org/10.1016%2Fj.healun.2006.05.013" class="external text external">10.1016/j.healun.2006.05.013</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/16962483  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/16962483'" tppabs="https://pubmed.ncbi.nlm.nih.gov/16962483" class="external text external">16962483</a>.</cite></span></li><li id="cite_note-29"> <span id="mw-reference-text-cite_note-29" class="mw-reference-text"><cite id="CITEREFMcWilliamsLevveyRussellMilne2003" class="citation journal cs1">McWilliams TJ, Levvey BJ, Russell PA, Milne DG, Snell GI (February 2003). "Interstitial pneumonitis associated with sirolimus: a dilemma for lung transplantation". <i>The Journal of Heart and Lung Transplantation</i>. <b>22</b> (2): 210–3. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2FS1053-2498%2802%2900564-8  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2FS1053-2498%2802%2900564-8'" tppabs="https://doi.org/10.1016%2FS1053-2498%2802%2900564-8" class="external text external">10.1016/S1053-2498(02)00564-8</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/12581772  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/12581772'" tppabs="https://pubmed.ncbi.nlm.nih.gov/12581772" class="external text external">12581772</a>.</cite></span></li><li id="cite_note-30"> <span id="mw-reference-text-cite_note-30" class="mw-reference-text"><cite id="CITEREFAparicioCalvoMedinaFernández2009" class="citation journal cs1">Aparicio G, Calvo MB, Medina V, Fernández O, Jiménez P, Lema M, Figueroa A, Antón Aparicio LM (August 2009). "Comprehensive lung injury pathology induced by mTOR inhibitors". <i>Clinical &amp; Translational Oncology</i>. <b>11</b> (8): 499–510. doi:<a href="javascript:if(confirm('https://doi.org/10.1007%2Fs12094-009-0394-y  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1007%2Fs12094-009-0394-y'" tppabs="https://doi.org/10.1007%2Fs12094-009-0394-y" class="external text external">10.1007/s12094-009-0394-y</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/19661024  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/19661024'" tppabs="https://pubmed.ncbi.nlm.nih.gov/19661024" class="external text external">19661024</a>.</cite></span></li><li id="cite_note-31"> <span id="mw-reference-text-cite_note-31" class="mw-reference-text"><cite id="CITEREFParisGoupilKernaonetFoulet-Rogé2012" class="citation journal cs1">Paris A, Goupil F, Kernaonet E, Foulet-Rogé A, Molinier O, Gagnadoux F, Lebas FX (January 2012). <a href="javascript:if(confirm('http://www.masson.fr/masson/S0761-8425(10)00421-3  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.masson.fr/masson/S0761-8425(10)00421-3'" tppabs="http://www.masson.fr/masson/S0761-8425(10)00421-3" class="external text external">"<span>[</span>Drug-induced pneumonitis due to sirolimus: an interaction with atorvastatin?<span>]</span>"</a>. <i>Revue des Maladies Respiratoires</i> (in French). <b>29</b> (1): 64–9. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.rmr.2010.03.026  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.rmr.2010.03.026'" tppabs="https://doi.org/10.1016%2Fj.rmr.2010.03.026" class="external text external">10.1016/j.rmr.2010.03.026</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/22240222  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/22240222'" tppabs="https://pubmed.ncbi.nlm.nih.gov/22240222" class="external text external">22240222</a>.</cite></span></li><li id="cite_note-32"> <span id="mw-reference-text-cite_note-32" class="mw-reference-text"><cite id="CITEREFMarotoHudesDutcherLogan2011" class="citation journal cs1">Maroto JP, Hudes G, Dutcher JP, Logan TF, White CS, Krygowski M, Cincotta M, Shapiro M, Duran I, Berkenblit A (May 2011). <a href="javascript:if(confirm('https://archive.is/20130415053309/http://www.jco.org/cgi/pmidlookup?view=long&pmid=21444868  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://archive.is/20130415053309/http://www.jco.org/cgi/pmidlookup?view=long&pmid=21444868'" tppabs="https://archive.is/20130415053309/http://www.jco.org/cgi/pmidlookup?view=long&pmid=21444868" class="external text external">"Drug-related pneumonitis in patients with advanced renal cell carcinoma treated with temsirolimus"</a>. <i>Journal of Clinical Oncology</i>. <b>29</b> (13): 1750–6. doi:<a href="javascript:if(confirm('https://doi.org/10.1200%2FJCO.2010.29.2235  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1200%2FJCO.2010.29.2235'" tppabs="https://doi.org/10.1200%2FJCO.2010.29.2235" class="external text external">10.1200/JCO.2010.29.2235</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/21444868  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/21444868'" tppabs="https://pubmed.ncbi.nlm.nih.gov/21444868" class="external text external">21444868</a>. Archived from <a href="javascript:if(confirm('http://www.jco.org/cgi/pmidlookup?view=long&pmid=21444868  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.jco.org/cgi/pmidlookup?view=long&pmid=21444868'" tppabs="http://www.jco.org/cgi/pmidlookup?view=long&pmid=21444868" class="external text external">the original</a> on 15 April 2013.</cite></span></li><li id="cite_note-33"> <span id="mw-reference-text-cite_note-33" class="mw-reference-text"><cite id="CITEREFErrastiIzquierdoMartínErrasti2010" class="citation journal cs1">Errasti P, Izquierdo D, Martín P, Errasti M, Slon F, Romero A, Lavilla FJ (October 2010). "Pneumonitis associated with mammalian target of rapamycin inhibitors in renal transplant recipients: a single-center experience". <i>Transplantation Proceedings</i>. <b>42</b> (8): 3053–4. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.transproceed.2010.07.066  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.transproceed.2010.07.066'" tppabs="https://doi.org/10.1016%2Fj.transproceed.2010.07.066" class="external text external">10.1016/j.transproceed.2010.07.066</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/20970608  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/20970608'" tppabs="https://pubmed.ncbi.nlm.nih.gov/20970608" class="external text external">20970608</a>.</cite></span></li><li id="cite_note-DailyMed-34"> <span id="mw-reference-text-cite_note-DailyMed-34" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3275b824-3f82-4151-2ab2-0036a9ba0acc  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3275b824-3f82-4151-2ab2-0036a9ba0acc'" tppabs="http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3275b824-3f82-4151-2ab2-0036a9ba0acc" class="external text external">"RAPAMUNE- sirolimus solution RAPAMUNE- sirolimus tablet, sugar coated"</a>. <i>dailymed.nlm.nih.gov</i>. DailyMed.</cite></span></li><li id="cite_note-35"> <span id="mw-reference-text-cite_note-35" class="mw-reference-text"><span><a href="javascript:if(confirm('https://www.drugs.com/pro/rapamune.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugs.com/pro/rapamune.html'" tppabs="https://www.drugs.com/pro/rapamune.html" class="external text external">FDA Professional Drug Information</a></span> on Rapamune. Accessed 29-09-2017.</span></li><li id="cite_note-36"> <span id="mw-reference-text-cite_note-36" class="mw-reference-text"><cite id="CITEREFEuvrardMorelonRostaingGoffin2012" class="citation journal cs1">Euvrard S, Morelon E, Rostaing L, Goffin E, Brocard A, Tromme I, Broeders N, del Marmol V, Chatelet V, Dompmartin A, Kessler M, Serra AL, Hofbauer GF, Pouteil-Noble C, Campistol JM, Kanitakis J, Roux AS, Decullier E, Dantal J (July 2012). <a href="javascript:if(confirm('https://www.zora.uzh.ch/id/eprint/64345/1/Euvrard_et_al_Sirolimus_and_secondary_skin-cancer.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.zora.uzh.ch/id/eprint/64345/1/Euvrard_et_al_Sirolimus_and_secondary_skin-cancer.pdf'" tppabs="https://www.zora.uzh.ch/id/eprint/64345/1/Euvrard_et_al_Sirolimus_and_secondary_skin-cancer.pdf" class="external text external">"Sirolimus and secondary skin-cancer prevention in kidney transplantation"</a> <span class="cs1-format">(PDF)</span>. <i>The New England Journal of Medicine</i>. <b>367</b> (4): 329–39. doi:<a href="javascript:if(confirm('https://doi.org/10.1056%2FNEJMoa1204166  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1056%2FNEJMoa1204166'" tppabs="https://doi.org/10.1056%2FNEJMoa1204166" class="external text external">10.1056/NEJMoa1204166</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/22830463  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/22830463'" tppabs="https://pubmed.ncbi.nlm.nih.gov/22830463" class="external text external">22830463</a>.</cite></span></li><li id="cite_note-Heitman_1991-37"> <span id="mw-reference-text-cite_note-Heitman_1991-37" class="mw-reference-text"><cite id="CITEREFHeitmanMovvaHall1991" class="citation journal cs1">Heitman J, Movva NR, Hall MN (1991). "Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast". <i>Science</i>. <b>253</b> (5022): 905–9. Bibcode:<a href="javascript:if(confirm('https://ui.adsabs.harvard.edu/abs/1991Sci...253..905H  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://ui.adsabs.harvard.edu/abs/1991Sci...253..905H'" tppabs="https://ui.adsabs.harvard.edu/abs/1991Sci...253..905H" class="external text external">1991Sci...253..905H</a>. doi:<a href="javascript:if(confirm('https://doi.org/10.1126%2Fscience.1715094  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1126%2Fscience.1715094'" tppabs="https://doi.org/10.1126%2Fscience.1715094" class="external text external">10.1126/science.1715094</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/1715094  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/1715094'" tppabs="https://pubmed.ncbi.nlm.nih.gov/1715094" class="external text external">1715094</a>.</cite></span></li><li id="cite_note-38"> <span id="mw-reference-text-cite_note-38" class="mw-reference-text"><cite id="CITEREFMcAlisterMahalatiPeltekianFraser2002" class="citation journal cs1">McAlister VC, Mahalati K, Peltekian KM, Fraser A, MacDonald AS (June 2002). "A clinical pharmacokinetic study of tacrolimus and sirolimus combination immunosuppression comparing simultaneous to separated administration". <i>Therapeutic Drug Monitoring</i>. <b>24</b> (3): 346–50. doi:<a href="javascript:if(confirm('https://doi.org/10.1097%2F00007691-200206000-00004  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1097%2F00007691-200206000-00004'" tppabs="https://doi.org/10.1097%2F00007691-200206000-00004" class="external text external">10.1097/00007691-200206000-00004</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/12021624  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/12021624'" tppabs="https://pubmed.ncbi.nlm.nih.gov/12021624" class="external text external">12021624</a>.</cite></span></li><li id="cite_note-Rapamycin_domains_and_primary_genes-39"> <span id="mw-reference-text-cite_note-Rapamycin_domains_and_primary_genes-39" class="mw-reference-text"><cite id="CITEREFSchweckeAparicioMolnárKönig1995" class="citation journal cs1">Schwecke T, Aparicio JF, Molnár I, König A, Khaw LE, Haydock SF, Oliynyk M, Caffrey P, Cortés J, Lester JB (August 1995). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC41241  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC41241'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC41241" class="external text external">"The biosynthetic gene cluster for the polyketide immunosuppressant rapamycin"</a>. <i>Proceedings of the National Academy of Sciences of the United States of America</i>. <b>92</b> (17): 7839–43. Bibcode:<a href="javascript:if(confirm('https://ui.adsabs.harvard.edu/abs/1995PNAS...92.7839S  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://ui.adsabs.harvard.edu/abs/1995PNAS...92.7839S'" tppabs="https://ui.adsabs.harvard.edu/abs/1995PNAS...92.7839S" class="external text external">1995PNAS...92.7839S</a>. doi:<a href="javascript:if(confirm('https://doi.org/10.1073%2Fpnas.92.17.7839  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1073%2Fpnas.92.17.7839'" tppabs="https://doi.org/10.1073%2Fpnas.92.17.7839" class="external text external">10.1073/pnas.92.17.7839</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC41241  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC41241'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC41241" class="external text external">41241</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/7644502  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/7644502'" tppabs="https://pubmed.ncbi.nlm.nih.gov/7644502" class="external text external">7644502</a>.</cite></span></li><li id="cite_note-prerapamycin-40"> <span id="mw-reference-text-cite_note-prerapamycin-40" class="mw-reference-text"><cite id="CITEREFGregoryGaisserLillHong2004" class="citation journal cs1">Gregory MA, Gaisser S, Lill RE, Hong H, Sheridan RM, Wilkinson B, Petkovic H, Weston AJ, Carletti I, Lee HL, Staunton J, Leadlay PF (May 2004). "Isolation and characterization of pre-rapamycin, the first macrocyclic intermediate in the biosynthesis of the immunosuppressant rapamycin by S. hygroscopicus". <i>Angewandte Chemie</i>. <b>43</b> (19): 2551–3. doi:<a href="javascript:if(confirm('https://doi.org/10.1002%2Fanie.200453764  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1002%2Fanie.200453764'" tppabs="https://doi.org/10.1002%2Fanie.200453764" class="external text external">10.1002/anie.200453764</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/15127450  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/15127450'" tppabs="https://pubmed.ncbi.nlm.nih.gov/15127450" class="external text external">15127450</a>.</cite></span></li><li id="cite_note-Rapamycin_genes-41"> <span id="mw-reference-text-cite_note-Rapamycin_genes-41" class="mw-reference-text"><cite id="CITEREFGregoryHongLillGaisser2006" class="citation journal cs1">Gregory MA, Hong H, Lill RE, Gaisser S, Petkovic H, Low L, Sheehan LS, Carletti I, Ready SJ, Ward MJ, Kaja AL, Weston AJ, Challis IR, Leadlay PF, Martin CJ, Wilkinson B, Sheridan RM (October 2006). "Rapamycin biosynthesis: Elucidation of gene product function". <i>Organic &amp; Biomolecular Chemistry</i>. <b>4</b> (19): 3565–8. doi:<a href="javascript:if(confirm('https://doi.org/10.1039%2Fb608813a  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1039%2Fb608813a'" tppabs="https://doi.org/10.1039%2Fb608813a" class="external text external">10.1039/b608813a</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/16990929  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/16990929'" tppabs="https://pubmed.ncbi.nlm.nih.gov/16990929" class="external text external">16990929</a>.</cite></span></li><li id="cite_note-rapamycin_report-42"> <span id="mw-reference-text-cite_note-rapamycin_report-42" class="mw-reference-text"><cite id="CITEREFGraziani2009" class="citation journal cs1">Graziani EI (May 2009). "Recent advances in the chemistry, biosynthesis and pharmacology of rapamycin analogs". <i>Natural Product Reports</i>. <b>26</b> (5): 602–9. doi:<a href="javascript:if(confirm('https://doi.org/10.1039%2Fb804602f  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1039%2Fb804602f'" tppabs="https://doi.org/10.1039%2Fb804602f" class="external text external">10.1039/b804602f</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/19387497  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/19387497'" tppabs="https://pubmed.ncbi.nlm.nih.gov/19387497" class="external text external">19387497</a>.</cite></span></li><li id="cite_note-43"> <span id="mw-reference-text-cite_note-43" class="mw-reference-text"><cite id="CITEREFGattoBoyneKelleherWalsh2006" class="citation journal cs1">Gatto GJ, Boyne MT, Kelleher NL, Walsh CT (March 2006). "Biosynthesis of pipecolic acid by RapL, a lysine cyclodeaminase encoded in the rapamycin gene cluster". <i>Journal of the American Chemical Society</i>. <b>128</b> (11): 3838–47. doi:<a href="javascript:if(confirm('https://doi.org/10.1021%2Fja0587603  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1021%2Fja0587603'" tppabs="https://doi.org/10.1021%2Fja0587603" class="external text external">10.1021/ja0587603</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/16536560  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/16536560'" tppabs="https://pubmed.ncbi.nlm.nih.gov/16536560" class="external text external">16536560</a>.</cite></span></li><li id="cite_note-rapG_rapH-44"> <span id="mw-reference-text-cite_note-rapG_rapH-44" class="mw-reference-text"><cite id="CITEREFAparicioMolnárSchweckeKönig1996" class="citation journal cs1">Aparicio JF, Molnár I, Schwecke T, König A, Haydock SF, Khaw LE, Staunton J, Leadlay PF (February 1996). "Organization of the biosynthetic gene cluster for rapamycin in Streptomyces hygroscopicus: analysis of the enzymatic domains in the modular polyketide synthase". <i>Gene</i>. <b>169</b> (1): 9–16. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2F0378-1119%2895%2900800-4  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2F0378-1119%2895%2900800-4'" tppabs="https://doi.org/10.1016%2F0378-1119%2895%2900800-4" class="external text external">10.1016/0378-1119(95)00800-4</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/8635756  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/8635756'" tppabs="https://pubmed.ncbi.nlm.nih.gov/8635756" class="external text external">8635756</a>.</cite></span></li><li id="cite_note-45"> <span id="mw-reference-text-cite_note-45" class="mw-reference-text"><cite id="CITEREFLiRaoVazzanaGoedegebuure2012" class="citation journal cs1">Li Q, Rao R, Vazzana J, Goedegebuure P, Odunsi K, Gillanders W, Shrikant PA (April 2012). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3311730  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3311730'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3311730" class="external text external">"Regulating mammalian target of rapamycin to tune vaccination-induced CD8(+) T cell responses for tumor immunity"</a>. <i>Journal of Immunology</i>. <b>188</b> (7): 3080–7. doi:<a href="javascript:if(confirm('https://doi.org/10.4049%2Fjimmunol.1103365  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.4049%2Fjimmunol.1103365'" tppabs="https://doi.org/10.4049%2Fjimmunol.1103365" class="external text external">10.4049/jimmunol.1103365</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3311730  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3311730'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3311730" class="external text external">3311730</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/22379028  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/22379028'" tppabs="https://pubmed.ncbi.nlm.nih.gov/22379028" class="external text external">22379028</a>.</cite></span></li><li id="cite_note-46"> <span id="mw-reference-text-cite_note-46" class="mw-reference-text"><cite id="CITEREFEastonHoughton2006" class="citation journal cs1">Easton JB, Houghton PJ (October 2006). <a href="javascript:if(confirm('https://doi.org/10.1038/sj.onc.1209886  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1038/sj.onc.1209886'" tppabs="https://doi.org/10.1038/sj.onc.1209886" class="external text external">"mTOR and cancer therapy"</a>. <i>Oncogene</i>. <b>25</b> (48): 6436–46. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1038%2Fsj.onc.1209886  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1038%2Fsj.onc.1209886'" tppabs="https://doi.org/10.1038%2Fsj.onc.1209886" class="external text external">10.1038/sj.onc.1209886</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/17041628  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/17041628'" tppabs="https://pubmed.ncbi.nlm.nih.gov/17041628" class="external text external">17041628</a>.</cite></span></li><li id="cite_note-Law2005-47"> <span id="mw-reference-text-cite_note-Law2005-47" class="mw-reference-text"><cite id="CITEREFLaw2005" class="citation journal cs1">Law BK (October 2005). "Rapamycin: an anti-cancer immunosuppressant?". <i>Critical Reviews in Oncology/Hematology</i>. <b>56</b> (1): 47–60. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.critrevonc.2004.09.009  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.critrevonc.2004.09.009'" tppabs="https://doi.org/10.1016%2Fj.critrevonc.2004.09.009" class="external text external">10.1016/j.critrevonc.2004.09.009</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/16039868  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/16039868'" tppabs="https://pubmed.ncbi.nlm.nih.gov/16039868" class="external text external">16039868</a>.</cite></span></li><li id="cite_note-48"> <span id="mw-reference-text-cite_note-48" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www.medpagetoday.com/MeetingCoverage/MGUCS/37404  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.medpagetoday.com/MeetingCoverage/MGUCS/37404'" tppabs="http://www.medpagetoday.com/MeetingCoverage/MGUCS/37404" class="external text external">"Fatal AEs Higher with mTOR Drugs in Cancer"</a>. Med Page Today. 17 February 2013.</cite></span></li><li id="cite_note-49"> <span id="mw-reference-text-cite_note-49" class="mw-reference-text"><cite id="CITEREFSunRosenbergWangZhou2005" class="citation journal cs1">Sun SY, Rosenberg LM, Wang X, Zhou Z, Yue P, Fu H, Khuri FR (August 2005). <a href="javascript:if(confirm('http://cancerres.aacrjournals.org/cgi/content/full/65/16/7052  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://cancerres.aacrjournals.org/cgi/content/full/65/16/7052'" tppabs="http://cancerres.aacrjournals.org/cgi/content/full/65/16/7052" class="external text external">"Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition"</a>. <i>Cancer Research</i>. <b>65</b> (16): 7052–8. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1158%2F0008-5472.CAN-05-0917  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1158%2F0008-5472.CAN-05-0917'" tppabs="https://doi.org/10.1158%2F0008-5472.CAN-05-0917" class="external text external">10.1158/0008-5472.CAN-05-0917</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/16103051  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/16103051'" tppabs="https://pubmed.ncbi.nlm.nih.gov/16103051" class="external text external">16103051</a>.</cite></span></li><li id="cite_note-Chan-50"> <span id="mw-reference-text-cite_note-Chan-50" class="mw-reference-text"><cite id="CITEREFChan2004" class="citation journal cs1">Chan S (October 2004). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409926  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409926'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409926" class="external text external">"Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer"</a>. <i>British Journal of Cancer</i>. <b>91</b> (8): 1420–4. doi:<a href="javascript:if(confirm('https://doi.org/10.1038%2Fsj.bjc.6602162  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1038%2Fsj.bjc.6602162'" tppabs="https://doi.org/10.1038%2Fsj.bjc.6602162" class="external text external">10.1038/sj.bjc.6602162</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409926  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409926'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409926" class="external text external">2409926</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/15365568  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/15365568'" tppabs="https://pubmed.ncbi.nlm.nih.gov/15365568" class="external text external">15365568</a>.</cite></span></li><li id="cite_note-ScienceDaily-51"> <span id="mw-reference-text-cite_note-ScienceDaily-51" class="mw-reference-text"><cite id="CITEREFWendelDe_StanchinaFridmanMalina2004" class="citation journal cs1">Wendel HG, De Stanchina E, Fridman JS, Malina A, Ray S, Kogan S, Cordon-Cardo C, Pelletier J, Lowe SW (March 2004). "Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy". <i>Nature</i>. <b>428</b> (6980): 332–7. Bibcode:<a href="javascript:if(confirm('https://ui.adsabs.harvard.edu/abs/2004Natur.428..332W  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://ui.adsabs.harvard.edu/abs/2004Natur.428..332W'" tppabs="https://ui.adsabs.harvard.edu/abs/2004Natur.428..332W" class="external text external">2004Natur.428..332W</a>. doi:<a href="javascript:if(confirm('https://doi.org/10.1038%2Fnature02369  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1038%2Fnature02369'" tppabs="https://doi.org/10.1038%2Fnature02369" class="external text external">10.1038/nature02369</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/15029198  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/15029198'" tppabs="https://pubmed.ncbi.nlm.nih.gov/15029198" class="external text external">15029198</a>. <a href="javascript:if(confirm('https://www.sciencedaily.com/releases/2004/03/040318073757.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.sciencedaily.com/releases/2004/03/040318073757.htm'" tppabs="https://www.sciencedaily.com/releases/2004/03/040318073757.htm" class="external text external">Lay summary</a> <span>–</span> <i>ScienceDaily</i> (18 March 2004).</cite></span></li><li id="cite_note-SignalingGateway-52"> <span id="mw-reference-text-cite_note-SignalingGateway-52" class="mw-reference-text"><cite id="CITEREFNovak2004" class="citation journal cs1">Novak, Kristine (May 2004). <a href="javascript:if(confirm('http://www.signaling-gateway.org/update/updates/200405/nrc1349.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.signaling-gateway.org/update/updates/200405/nrc1349.html'" tppabs="http://www.signaling-gateway.org/update/updates/200405/nrc1349.html" class="external text external">"Therapeutics: Means to an end"</a>. <i>Nature Reviews Cancer</i>. <b>4</b> (5): 332. doi:<a href="javascript:if(confirm('https://doi.org/10.1038%2Fnrc1349  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1038%2Fnrc1349'" tppabs="https://doi.org/10.1038%2Fnrc1349" class="external text external">10.1038/nrc1349</a>.</cite>
</span></li><li id="cite_note-53"> <span id="mw-reference-text-cite_note-53" class="mw-reference-text"><cite id="CITEREFTuberous_Sclerosis_Alliance2009" class="citation web cs1">Tuberous Sclerosis Alliance (October 2009). <a href="javascript:if(confirm('https://web.archive.org/web/20090122192859/http://tsalliance.org/pages.aspx?content=370  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20090122192859/http://tsalliance.org/pages.aspx?content=370'" tppabs="https://web.archive.org/web/20090122192859/http://tsalliance.org/pages.aspx?content=370" class="external text external">"Current Clinical Trials"</a>. Archived from <a href="javascript:if(confirm('http://www.tsalliance.org/pages.aspx?content=370  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.tsalliance.org/pages.aspx?content=370'" tppabs="http://www.tsalliance.org/pages.aspx?content=370" class="external text external">the original</a> on 22 January 2009<span class="reference-accessdate">. Retrieved <span class="nowrap">14 October</span> 2009</span>.</cite></span></li><li id="cite_note-54"> <span id="mw-reference-text-cite_note-54" class="mw-reference-text"><cite id="CITEREFBalestriNeriPatriziAngileri2015" class="citation journal cs1">Balestri R, Neri I, Patrizi A, Angileri L, Ricci L, Magnano M (January 2015). "Analysis of current data on the use of topical rapamycin in the treatment of facial angiofibromas in tuberous sclerosis complex". <i>Journal of the European Academy of Dermatology and Venereology</i>. <b>29</b> (1): 14–20. doi:<a href="javascript:if(confirm('https://doi.org/10.1111%2Fjdv.12665  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1111%2Fjdv.12665'" tppabs="https://doi.org/10.1111%2Fjdv.12665" class="external text external">10.1111/jdv.12665</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/25174683  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/25174683'" tppabs="https://pubmed.ncbi.nlm.nih.gov/25174683" class="external text external">25174683</a>.</cite></span></li><li id="cite_note-Apelo2016rev-55"> <span id="mw-reference-text-cite_note-Apelo2016rev-55" class="mw-reference-text"><cite id="CITEREFArriola_ApeloLamming2016" class="citation journal cs1">Arriola Apelo SI, Lamming DW (July 2016). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4906330  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4906330'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4906330" class="external text external">"Rapamycin: An InhibiTOR of Aging Emerges From the Soil of Easter Island"</a>. <i>The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences</i>. <b>71</b> (7): 841–9. doi:<a href="javascript:if(confirm('https://doi.org/10.1093%2Fgerona%2Fglw090  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1093%2Fgerona%2Fglw090'" tppabs="https://doi.org/10.1093%2Fgerona%2Fglw090" class="external text external">10.1093/gerona/glw090</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4906330  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4906330'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4906330" class="external text external">4906330</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/27208895  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/27208895'" tppabs="https://pubmed.ncbi.nlm.nih.gov/27208895" class="external text external">27208895</a>. <q>A diverse and severe set of negative side effects likely preclude the wide-scale use of rapamycin and its analogs as a prolongevity agent.</q></cite></span></li><li id="cite_note-56"> <span id="mw-reference-text-cite_note-56" class="mw-reference-text"><cite id="CITEREFWeichhartHengstschlägerLinke2015" class="citation journal cs1">Weichhart T, Hengstschläger M, Linke M (October 2015). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6095456  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6095456'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6095456" class="external text external">"Regulation of innate immune cell function by mTOR"</a>. <i>Nature Reviews. Immunology</i>. <b>15</b> (10): 599–614. doi:<a href="javascript:if(confirm('https://doi.org/10.1038%2Fnri3901  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1038%2Fnri3901'" tppabs="https://doi.org/10.1038%2Fnri3901" class="external text external">10.1038/nri3901</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6095456  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6095456'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6095456" class="external text external">6095456</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/26403194  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/26403194'" tppabs="https://pubmed.ncbi.nlm.nih.gov/26403194" class="external text external">26403194</a>.</cite></span></li><li id="cite_note-Oaks2016rev-57"> <span id="mw-reference-text-cite_note-Oaks2016rev-57" class="mw-reference-text"><cite id="CITEREFOaksWinansHuangBanki2016" class="citation journal cs1">Oaks Z, Winans T, Huang N, Banki K, Perl A (December 2016). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5314949  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5314949'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5314949" class="external text external">"Activation of the Mechanistic Target of Rapamycin in SLE: Explosion of Evidence in the Last Five Years"</a>. <i>Current Rheumatology Reports</i>. <b>18</b> (12): 73. doi:<a href="javascript:if(confirm('https://doi.org/10.1007%2Fs11926-016-0622-8  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1007%2Fs11926-016-0622-8'" tppabs="https://doi.org/10.1007%2Fs11926-016-0622-8" class="external text external">10.1007/s11926-016-0622-8</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5314949  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5314949'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5314949" class="external text external">5314949</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/27812954  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/27812954'" tppabs="https://pubmed.ncbi.nlm.nih.gov/27812954" class="external text external">27812954</a>.</cite></span></li><li id="cite_note-58"> <span id="mw-reference-text-cite_note-58" class="mw-reference-text"><cite id="CITEREFGarcía2019" class="citation journal cs1">García, M (2019). "The Use of Topical Rapamycin in the Treatment of Superficial Lymphatic Malformations". <i>JAAD</i>. <b>80</b> (2): 508–15. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.jaad.2018.09.050  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.jaad.2018.09.050'" tppabs="https://doi.org/10.1016%2Fj.jaad.2018.09.050" class="external text external">10.1016/j.jaad.2018.09.050</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/30296533  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/30296533'" tppabs="https://pubmed.ncbi.nlm.nih.gov/30296533" class="external text external">30296533</a>.</cite></span></li><li id="cite_note-59"> <span id="mw-reference-text-cite_note-59" class="mw-reference-text"><cite id="CITEREFRiveraClacksonNatesanPollock1996" class="citation journal cs1">Rivera VM, Clackson T, Natesan S, Pollock R, Amara JF, Keenan T, Magari SR, Phillips T, Courage NL, Cerasoli F, Holt DA, Gilman M (September 1996). "A humanized system for pharmacologic control of gene expression". <i>Nature Medicine</i>. <b>2</b> (9): 1028–32. doi:<a href="javascript:if(confirm('https://doi.org/10.1038%2Fnm0996-1028  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1038%2Fnm0996-1028'" tppabs="https://doi.org/10.1038%2Fnm0996-1028" class="external text external">10.1038/nm0996-1028</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/8782462  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/8782462'" tppabs="https://pubmed.ncbi.nlm.nih.gov/8782462" class="external text external">8782462</a>.</cite></span></li></ol></div></div>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="External_links">External links</h2></summary>
    
<table role="presentation" class="mbox-small  sistersitebox" style="background-color:#f9f9f9;border:1px solid #aaa;color:#000">
<tbody><tr>
<td class="mbox-image"><figure-inline class="noviewer"><span><img src="../I/m/Commons-logo.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Commons-logo.svg.png" data-file-width="1024" data-file-height="1376" data-file-type="drawing" height="40" width="30"></span></figure-inline></td>
<td class="mbox-text plainlist">Wikimedia Commons has media related to <i><b><a href="javascript:if(confirm('https://commons.wikimedia.org/wiki/Category:Sirolimus  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://commons.wikimedia.org/wiki/Category:Sirolimus'" tppabs="https://commons.wikimedia.org/wiki/Category:Sirolimus" title="commons:Category:Sirolimus" class="external"><span style=" ">Sirolimus</span></a></b></i>.</td></tr>
</tbody></table>
<style data-mw-deduplicate="TemplateStyles:r886047268">.mw-parser-output .refbegin{font-size:90%;margin-bottom:0.5em}.mw-parser-output .refbegin-hanging-indents>ul{list-style-type:none;margin-left:0}.mw-parser-output .refbegin-hanging-indents>ul>li,.mw-parser-output .refbegin-hanging-indents>dl>dd{margin-left:0;padding-left:3.2em;text-indent:-3.2em;list-style:none}.mw-parser-output .refbegin-100{font-size:100%}</style><div class="refbegin reflist   " style="">
<ul><li><cite id="CITEREFBenjaminColombiMoroniHall2011" class="citation journal cs1">Benjamin D, Colombi M, Moroni C, Hall MN (October 2011). "Rapamycin passes the torch: a new generation of mTOR inhibitors". <i>Nature Reviews. Drug Discovery</i>. <b>10</b> (11): 868–80. doi:<a href="javascript:if(confirm('https://doi.org/10.1038%2Fnrd3531  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1038%2Fnrd3531'" tppabs="https://doi.org/10.1038%2Fnrd3531" class="external text external">10.1038/nrd3531</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/22037041  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/22037041'" tppabs="https://pubmed.ncbi.nlm.nih.gov/22037041" class="external text external">22037041</a>.</cite></li></ul>
</div>

<div role="navigation" class="navbox" aria-labelledby="Immunosuppressive_drugs_/_Immunosuppressants_(L04)" style="padding:3px"><table class="nowraplinks mw-collapsible autocollapse navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Immunosuppressive_drugs_/_Immunosuppressants_(L04)" style="font-size:114%;margin:0 4em">Immunosuppressive drugs<span>&nbsp;</span>/ Immunosuppressants (L04)</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%">Intracellular<br>(initiation)</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">Antimetabolites</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>purine synthesis inhibitors</i>
<ul><li><a href="Azathioprine.htm" tppabs="https://ptable.com/wiki/compounds/A/Azathioprine" title="Azathioprine">Azathioprine</a></li>
<li><a href="Mycophenolic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Mycophenolic_acid" title="Mycophenolic acid">Mycophenolic acid</a></li></ul></li></ul>

<ul><li><i>pyrimidine synthesis inhibitors</i>
<ul><li><a href="Leflunomide.htm" tppabs="https://ptable.com/wiki/compounds/A/Leflunomide" title="Leflunomide">Leflunomide</a></li>
<li>Teriflunomide</li></ul></li></ul>

<ul><li><i>antifolate</i>
<ul><li><a href="Methotrexate.htm" tppabs="https://ptable.com/wiki/compounds/A/Methotrexate" title="Methotrexate">Methotrexate</a></li></ul></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Macrolides/<br>other <a href="Interleukin_2.htm" tppabs="https://ptable.com/wiki/compounds/A/Interleukin_2" title="Interleukin 2">IL-2</a> inhibitors</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>FKBP/Cyclophilin/Calcineurin</i>
<ul><li><a href="Tacrolimus.htm" tppabs="https://ptable.com/wiki/compounds/A/Tacrolimus" title="Tacrolimus">Tacrolimus</a></li>
<li><a href="Ciclosporin.htm" tppabs="https://ptable.com/wiki/compounds/A/Ciclosporin" title="Ciclosporin">Ciclosporin</a></li>
<li><a href="Pimecrolimus.htm" tppabs="https://ptable.com/wiki/compounds/A/Pimecrolimus" title="Pimecrolimus">Pimecrolimus</a></li></ul></li></ul>

<ul><li>Abetimus</li>
<li>Gusperimus</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">IMiDs</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Lenalidomide.htm" tppabs="https://ptable.com/wiki/compounds/A/Lenalidomide" title="Lenalidomide">Lenalidomide</a></li>
<li>Pomalidomide</li>
<li><a href="Thalidomide.htm" tppabs="https://ptable.com/wiki/compounds/A/Thalidomide" title="Thalidomide">Thalidomide</a></li>
<li><i>PDE4 inhibitor</i>
<ul><li>Apremilast</li></ul></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Intracellular<br>(reception)</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">IL-1 receptor antagonists</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Anakinra.htm" tppabs="https://ptable.com/wiki/compounds/A/Anakinra" title="Anakinra">Anakinra</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">mTOR</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Sirolimus.htm" tppabs="https://ptable.com/wiki/compounds/A/Sirolimus" title="Sirolimus">Sirolimus</a></li>
<li><a href="Everolimus.htm" tppabs="https://ptable.com/wiki/compounds/A/Everolimus" title="Everolimus">Everolimus</a></li>
<li>Ridaforolimus</li>
<li><a href="Temsirolimus.htm" tppabs="https://ptable.com/wiki/compounds/A/Temsirolimus" title="Temsirolimus">Temsirolimus</a></li>
<li>Umirolimus</li>
<li>Zotarolimus</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Extracellular</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%"><a href="Antibody.htm" tppabs="https://ptable.com/wiki/compounds/A/Antibody" title="Antibody">Antibodies</a></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">Monoclonal</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">Serum target<br>(noncellular)</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Complement component 5</i>
<ul><li>Eculizumab</li></ul></li>
<li><i>TNF</i>
<ul><li><a href="Adalimumab.htm" tppabs="https://ptable.com/wiki/compounds/A/Adalimumab" title="Adalimumab">Adalimumab</a></li>
<li>Afelimomab</li>
<li>Certolizumab pegol</li>
<li>Golimumab</li>
<li><a href="Infliximab.htm" tppabs="https://ptable.com/wiki/compounds/A/Infliximab" title="Infliximab">Infliximab</a></li>
<li>Nerelimomab</li></ul></li>
<li><i>Interleukin 5</i>
<ul><li>Mepolizumab</li></ul></li>
<li><i>Immunoglobulin E</i>
<ul><li><a href="Omalizumab.htm" tppabs="https://ptable.com/wiki/compounds/A/Omalizumab" title="Omalizumab">Omalizumab</a></li></ul></li></ul>

<ul><li><i>Interferon</i>
<ul><li>Faralimomab</li></ul></li></ul>

<ul><li><i>IL-6</i>
<ul><li>Elsilimomab</li></ul></li></ul>

<ul><li><i>IL-12 and IL-23</i>
<ul><li>Lebrikizumab</li>
<li>Ustekinumab</li></ul></li></ul>

<ul><li><i>IL-17A</i>
<ul><li>Secukinumab</li></ul></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Cellular<br>target</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>CD3</i>
<ul><li><a href="Muromonab-CD3.htm" tppabs="https://ptable.com/wiki/compounds/A/Muromonab-CD3" title="Muromonab-CD3">Muromonab-CD3</a></li>
<li>Otelixizumab</li>
<li>Teplizumab</li>
<li>Visilizumab</li></ul></li>
<li><i>CD4</i>
<ul><li>Clenoliximab</li>
<li>Keliximab</li>
<li>Zanolimumab</li></ul></li>
<li><i>CD11a</i>
<ul><li>Efalizumab</li></ul></li>
<li><i>CD18</i>
<ul><li>Erlizumab</li></ul></li>
<li><i>CD20</i>
<ul><li>Obinutuzumab</li>
<li><a href="Rituximab.htm" tppabs="https://ptable.com/wiki/compounds/A/Rituximab" title="Rituximab">Rituximab</a></li>
<li>Ocrelizumab</li>
<li>Pascolizumab</li></ul></li>
<li><i>CD23</i>
<ul><li>Gomiliximab</li>
<li>Lumiliximab</li></ul></li>
<li><i>CD40</i>
<ul><li>Teneliximab</li>
<li>Toralizumab</li></ul></li>
<li><i>CD62L/L-selectin</i>
<ul><li>Aselizumab</li></ul></li>
<li><i>CD80</i>
<ul><li>Galiximab</li></ul></li>
<li><i>CD147/Basigin</i>
<ul><li>Gavilimomab</li></ul></li>
<li><i>CD154</i>
<ul><li>Ruplizumab</li></ul></li></ul>

<ul><li><i>BLyS</i>
<ul><li>Belimumab</li>
<li>Blisibimod</li></ul></li>
<li><i>CTLA-4</i>
<ul><li>Ipilimumab</li>
<li>Tremelimumab</li></ul></li>
<li><i>CAT</i>
<ul><li>Bertilimumab</li>
<li>Lerdelimumab</li>
<li>Metelimumab</li></ul></li>
<li><i>Integrin</i>
<ul><li>Natalizumab</li>
<li>Vedolizumab</li></ul></li>
<li><i>Interleukin-6 receptor</i>
<ul><li>Tocilizumab</li></ul></li>
<li><i>LFA-1</i>
<ul><li>Odulimomab</li></ul></li></ul>

<ul><li><i>IL-2 receptor/CD25</i>
<ul><li><a href="Basiliximab.htm" tppabs="https://ptable.com/wiki/compounds/A/Basiliximab" title="Basiliximab">Basiliximab</a></li>
<li><a href="Daclizumab.htm" tppabs="https://ptable.com/wiki/compounds/A/Daclizumab" title="Daclizumab">Daclizumab</a></li>
<li>Inolimomab</li></ul></li></ul>

<ul><li><i>T-lymphocyte</i> (Zolimomab aritox)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Unsorted</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Atorolimumab</li>
<li>Cedelizumab</li>
<li>Fontolizumab</li>
<li>Maslimomab</li>
<li>Morolimumab</li>
<li>Pexelizumab</li>
<li>Reslizumab</li>
<li>Rovelizumab</li>
<li>Siplizumab</li>
<li>Talizumab</li>
<li>Telimomab aritox</li>
<li>Vapaliximab</li>
<li>Vepalimomab</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Polyclonal</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Anti-thymocyte globulin</li>
<li>Anti-lymphocyte globulin</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">-cept (Fusion)</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>CTLA-4</i>
<ul><li>Abatacept</li>
<li>Belatacept</li></ul></li>
<li><i>TNF inhibitor</i>
<ul><li><a href="Etanercept.htm" tppabs="https://ptable.com/wiki/compounds/A/Etanercept" title="Etanercept">Etanercept</a></li>
<li>Pegsunercept</li></ul></li>
<li>Aflibercept</li>
<li><a href="Alefacept.htm" tppabs="https://ptable.com/wiki/compounds/A/Alefacept" title="Alefacept">Alefacept</a></li>
<li>Rilonacept</li></ul>
</div></td></tr></tbody></table><div></div></td></tr></tbody></table></div>
<div role="navigation" class="navbox" aria-labelledby="Xenobiotic-sensing_receptor_modulators" style="padding:3px"><table class="nowraplinks hlist mw-collapsible mw-collapsed navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Xenobiotic-sensing_receptor_modulators" style="font-size:114%;margin:0 4em">Xenobiotic-sensing receptor modulators</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;"><abbr>CAR</abbr></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <span class="new">6,7-Dimethylesculetin</span></li>
<li><a href="Amiodarone.htm" tppabs="https://ptable.com/wiki/compounds/A/Amiodarone" title="Amiodarone">Amiodarone</a></li>
<li><a href="Artemisinin.htm" tppabs="https://ptable.com/wiki/compounds/A/Artemisinin" title="Artemisinin">Artemisinin</a></li>
<li><span class="new">Benfuracarb</span></li>
<li><a href="Carbamazepine.htm" tppabs="https://ptable.com/wiki/compounds/A/Carbamazepine" title="Carbamazepine">Carbamazepine</a></li>
<li><a href="Carvedilol.htm" tppabs="https://ptable.com/wiki/compounds/A/Carvedilol" title="Carvedilol">Carvedilol</a></li>
<li><a href="Chlorpromazine.htm" tppabs="https://ptable.com/wiki/compounds/A/Chlorpromazine" title="Chlorpromazine">Chlorpromazine</a></li>
<li><a href="Chrysin.htm" tppabs="https://ptable.com/wiki/compounds/A/Chrysin" title="Chrysin">Chrysin</a></li>
<li><span class="new">CITCO</span></li>
<li><a href="Clotrimazole.htm" tppabs="https://ptable.com/wiki/compounds/A/Clotrimazole" title="Clotrimazole">Clotrimazole</a></li>
<li><a href="Cyclophosphamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Cyclophosphamide" title="Cyclophosphamide">Cyclophosphamide</a></li>
<li><a href="Cypermethrin.htm" tppabs="https://ptable.com/wiki/compounds/A/Cypermethrin" title="Cypermethrin">Cypermethrin</a></li>
<li><a href="Dehydroepiandrosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Dehydroepiandrosterone" title="Dehydroepiandrosterone">DHEA</a> (prasterone)</li>
<li><a href="Efavirenz.htm" tppabs="https://ptable.com/wiki/compounds/A/Efavirenz" title="Efavirenz">Efavirenz</a></li>
<li><a href="Ellagic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Ellagic_acid" title="Ellagic acid">Ellagic acid</a></li>
<li><a href="Griseofulvin.htm" tppabs="https://ptable.com/wiki/compounds/A/Griseofulvin" title="Griseofulvin">Griseofulvin</a></li>
<li><a href="Methoxychlor.htm" tppabs="https://ptable.com/wiki/compounds/A/Methoxychlor" title="Methoxychlor">Methoxychlor</a></li>
<li><a href="Mifepristone.htm" tppabs="https://ptable.com/wiki/compounds/A/Mifepristone" title="Mifepristone">Mifepristone</a></li>
<li><a href="Nefazodone.htm" tppabs="https://ptable.com/wiki/compounds/A/Nefazodone" title="Nefazodone">Nefazodone</a></li>
<li><a href="Nevirapine.htm" tppabs="https://ptable.com/wiki/compounds/A/Nevirapine" title="Nevirapine">Nevirapine</a></li>
<li><a href="Nicardipine.htm" tppabs="https://ptable.com/wiki/compounds/A/Nicardipine" title="Nicardipine">Nicardipine</a></li>
<li><span class="new">Octicizer</span></li>
<li><a href="Permethrin.htm" tppabs="https://ptable.com/wiki/compounds/A/Permethrin" title="Permethrin">Permethrin</a></li>
<li><a href="Phenobarbital.htm" tppabs="https://ptable.com/wiki/compounds/A/Phenobarbital" title="Phenobarbital">Phenobarbital</a></li>
<li><a href="Phenytoin.htm" tppabs="https://ptable.com/wiki/compounds/A/Phenytoin" title="Phenytoin">Phenytoin</a></li>
<li>Pregnanedione (5β-dihydroprogesterone)</li>
<li><a href="Reserpine.htm" tppabs="https://ptable.com/wiki/compounds/A/Reserpine" title="Reserpine">Reserpine</a></li>
<li><span class="new">TCPOBOP</span></li>
<li><a href="Telmisartan.htm" tppabs="https://ptable.com/wiki/compounds/A/Telmisartan" title="Telmisartan">Telmisartan</a></li>
<li><a href="Tolnaftate.htm" tppabs="https://ptable.com/wiki/compounds/A/Tolnaftate" title="Tolnaftate">Tolnaftate</a></li>
<li><a href="Troglitazone.htm" tppabs="https://ptable.com/wiki/compounds/A/Troglitazone" title="Troglitazone">Troglitazone</a></li>
<li><a href="Valproic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Valproic_acid" title="Valproic acid" class="mw-redirect">Valproic acid</a></li></ul>

<ul><li><i>Antagonists:</i> <span class="new">3,17β-Estradiol</span></li>
<li><span class="new">3α-Androstanol</span></li>
<li>3α-Androstenol</li>
<li><span class="new">3β-Androstanol</span></li>
<li><span class="new">17-Androstanol</span></li>
<li><a href="Allyl_isothiocyanate.htm" tppabs="https://ptable.com/wiki/compounds/A/Allyl_isothiocyanate" title="Allyl isothiocyanate">AITC</a></li>
<li>Ethinylestradiol</li>
<li>Meclizine</li>
<li><span class="new">Nigramide J</span></li>
<li><a href="Okadaic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Okadaic_acid" title="Okadaic acid">Okadaic acid</a></li>
<li>PK-11195</li>
<li><span class="new">S-07662</span></li>
<li><span class="new">T-0901317</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;"><abbr>PXR</abbr></th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> 17α-Hydroxypregnenolone</li>
<li>17α-Hydroxyprogesterone</li>
<li><a href="Androstenedione.htm" tppabs="https://ptable.com/wiki/compounds/A/%CE%944-Androstenedione" title="Δ4-Androstenedione" class="mw-redirect">Δ<sup>4</sup>-Androstenedione</a></li>
<li><a href="Androstenediol.htm" tppabs="https://ptable.com/wiki/compounds/A/%CE%945-Androstenediol" title="Δ5-Androstenediol" class="mw-redirect">Δ<sup>5</sup>-Androstenediol</a></li>
<li>Δ<sup>5</sup>-Androstenedione</li>
<li><span class="new">AA-861</span></li>
<li>Allopregnanediol</li>
<li><a href="5α-Dihydroprogesterone.htm" tppabs="https://ptable.com/wiki/compounds/A/5%CE%B1-Dihydroprogesterone" title="5α-Dihydroprogesterone">Allopregnanedione (5α-dihydroprogesterone)</a></li>
<li><a href="Allopregnanolone.htm" tppabs="https://ptable.com/wiki/compounds/A/Allopregnanolone" title="Allopregnanolone">Allopregnanolone (brexanolone)</a></li>
<li>Alpha-Lipoic acid</li>
<li>Ambrisentan</li>
<li>AMI-193</li>
<li>Amlodipine besylate</li>
<li>Antimycotics</li>
<li><a href="Artemisinin.htm" tppabs="https://ptable.com/wiki/compounds/A/Artemisinin" title="Artemisinin">Artemisinin</a></li>
<li><a href="Aurothioglucose.htm" tppabs="https://ptable.com/wiki/compounds/A/Aurothioglucose" title="Aurothioglucose">Aurothioglucose</a></li>
<li>Bile acids</li>
<li><a href="Bithionol.htm" tppabs="https://ptable.com/wiki/compounds/A/Bithionol" title="Bithionol">Bithionol</a></li>
<li><a href="Bosentan.htm" tppabs="https://ptable.com/wiki/compounds/A/Bosentan" title="Bosentan">Bosentan</a></li>
<li><span class="new">Bumecaine</span></li>
<li>Cafestol</li>
<li><a href="Cephaloridine.htm" tppabs="https://ptable.com/wiki/compounds/A/Cephaloridine" title="Cephaloridine">Cephaloridine</a></li>
<li><a href="Cefradine.htm" tppabs="https://ptable.com/wiki/compounds/A/Cephradine" title="Cephradine" class="mw-redirect">Cephradine</a></li>
<li><a href="Chlorpromazine.htm" tppabs="https://ptable.com/wiki/compounds/A/Chlorpromazine" title="Chlorpromazine">Chlorpromazine</a></li>
<li>Ciglitazone</li>
<li><a href="Clindamycin.htm" tppabs="https://ptable.com/wiki/compounds/A/Clindamycin" title="Clindamycin">Clindamycin</a></li>
<li>Clofenvinfos</li>
<li><a href="Chloroxine.htm" tppabs="https://ptable.com/wiki/compounds/A/Chloroxine" title="Chloroxine">Chloroxine</a></li>
<li><a href="Clotrimazole.htm" tppabs="https://ptable.com/wiki/compounds/A/Clotrimazole" title="Clotrimazole">Clotrimazole</a></li>
<li><a href="Colforsin.htm" tppabs="https://ptable.com/wiki/compounds/A/Colforsin" title="Colforsin">Colforsin</a></li>
<li><a href="Corticosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Corticosterone" title="Corticosterone">Corticosterone</a></li>
<li><a href="Cyclophosphamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Cyclophosphamide" title="Cyclophosphamide">Cyclophosphamide</a></li>
<li>Cyproterone acetate</li>
<li><a href="Demecolcine.htm" tppabs="https://ptable.com/wiki/compounds/A/Demecolcine" title="Demecolcine">Demecolcine</a></li>
<li><a href="Dexamethasone.htm" tppabs="https://ptable.com/wiki/compounds/A/Dexamethasone" title="Dexamethasone">Dexamethasone</a></li>
<li><a href="Dehydroepiandrosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Dehydroepiandrosterone" title="Dehydroepiandrosterone">DHEA</a> (prasterone)</li>
<li><a href="Dehydroepiandrosterone_sulfate.htm" tppabs="https://ptable.com/wiki/compounds/A/Dehydroepiandrosterone_sulfate" title="Dehydroepiandrosterone sulfate">DHEA-S</a> (prasterone sulfate)</li>
<li>Dibunate sodium</li>
<li>Diclazuril</li>
<li><a href="Dicloxacillin.htm" tppabs="https://ptable.com/wiki/compounds/A/Dicloxacillin" title="Dicloxacillin">Dicloxacillin</a></li>
<li><a href="Dimercaprol.htm" tppabs="https://ptable.com/wiki/compounds/A/Dimercaprol" title="Dimercaprol">Dimercaprol</a></li>
<li><span class="new">Dinaline</span></li>
<li><a href="Docetaxel.htm" tppabs="https://ptable.com/wiki/compounds/A/Docetaxel" title="Docetaxel">Docetaxel</a></li>
<li>Docusate calcium</li>
<li>Dodecylbenzenesulfonic acid</li>
<li>Dronabinol</li>
<li>Droxidopa</li>
<li><a href="Vinburnine.htm" tppabs="https://ptable.com/wiki/compounds/A/Eburnamonine" title="Eburnamonine" class="mw-redirect">Eburnamonine</a></li>
<li>Ecopipam</li>
<li>Enzacamene</li>
<li>Epothilone B</li>
<li><a href="Erythromycin.htm" tppabs="https://ptable.com/wiki/compounds/A/Erythromycin" title="Erythromycin">Erythromycin</a></li>
<li>Famprofazone</li>
<li><span class="new">Febantel</span></li>
<li><a href="Felodipine.htm" tppabs="https://ptable.com/wiki/compounds/A/Felodipine" title="Felodipine">Felodipine</a></li>
<li><a href="Fenbendazole.htm" tppabs="https://ptable.com/wiki/compounds/A/Fenbendazole" title="Fenbendazole">Fenbendazole</a></li>
<li><a href="Fentanyl.htm" tppabs="https://ptable.com/wiki/compounds/A/Fentanyl" title="Fentanyl">Fentanyl</a></li>
<li><a href="Flucloxacillin.htm" tppabs="https://ptable.com/wiki/compounds/A/Flucloxacillin" title="Flucloxacillin">Flucloxacillin</a></li>
<li><a href="Fluorometholone.htm" tppabs="https://ptable.com/wiki/compounds/A/Fluorometholone" title="Fluorometholone">Fluorometholone</a></li>
<li><a href="Griseofulvin.htm" tppabs="https://ptable.com/wiki/compounds/A/Griseofulvin" title="Griseofulvin">Griseofulvin</a></li>
<li>Guggulsterone</li>
<li><a href="Haloprogin.htm" tppabs="https://ptable.com/wiki/compounds/A/Haloprogin" title="Haloprogin">Haloprogin</a></li>
<li>Hetacillin potassium</li>
<li><a href="Hyperforin.htm" tppabs="https://ptable.com/wiki/compounds/A/Hyperforin" title="Hyperforin">Hyperforin</a></li>
<li><i>Hypericum perforatum</i> (St John's wort)</li>
<li>Indinavir sulfate</li>
<li>Lasalocid sodium</li>
<li><a href="Levothyroxine.htm" tppabs="https://ptable.com/wiki/compounds/A/Levothyroxine" title="Levothyroxine">Levothyroxine</a></li>
<li><a href="Linolenic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Linolenic_acid" title="Linolenic acid">Linolenic acid</a></li>
<li><span class="new">LOE-908</span></li>
<li><a href="Loratadine.htm" tppabs="https://ptable.com/wiki/compounds/A/Loratadine" title="Loratadine">Loratadine</a></li>
<li><a href="Lovastatin.htm" tppabs="https://ptable.com/wiki/compounds/A/Lovastatin" title="Lovastatin">Lovastatin</a></li>
<li>Meclizine</li>
<li><a href="Metacycline.htm" tppabs="https://ptable.com/wiki/compounds/A/Metacycline" title="Metacycline">Metacycline</a></li>
<li><a href="Methylprednisolone.htm" tppabs="https://ptable.com/wiki/compounds/A/Methylprednisolone" title="Methylprednisolone">Methylprednisolone</a></li>
<li><a href="Metyrapone.htm" tppabs="https://ptable.com/wiki/compounds/A/Metyrapone" title="Metyrapone">Metyrapone</a></li>
<li><a href="Mevastatin.htm" tppabs="https://ptable.com/wiki/compounds/A/Mevastatin" title="Mevastatin">Mevastatin</a></li>
<li><a href="Mifepristone.htm" tppabs="https://ptable.com/wiki/compounds/A/Mifepristone" title="Mifepristone">Mifepristone</a></li>
<li><a href="Nafcillin.htm" tppabs="https://ptable.com/wiki/compounds/A/Nafcillin" title="Nafcillin">Nafcillin</a></li>
<li><a href="Nicardipine.htm" tppabs="https://ptable.com/wiki/compounds/A/Nicardipine" title="Nicardipine">Nicardipine</a></li>
<li><a href="Nicotine.htm" tppabs="https://ptable.com/wiki/compounds/A/Nicotine" title="Nicotine">Nicotine</a></li>
<li><a href="Nifedipine.htm" tppabs="https://ptable.com/wiki/compounds/A/Nifedipine" title="Nifedipine">Nifedipine</a></li>
<li>Nilvadipine</li>
<li><a href="Nisoldipine.htm" tppabs="https://ptable.com/wiki/compounds/A/Nisoldipine" title="Nisoldipine">Nisoldipine</a></li>
<li>Norelgestromin</li>
<li><a href="Omeprazole.htm" tppabs="https://ptable.com/wiki/compounds/A/Omeprazole" title="Omeprazole">Omeprazole</a></li>
<li><a href="Orlistat.htm" tppabs="https://ptable.com/wiki/compounds/A/Orlistat" title="Orlistat">Orlistat</a></li>
<li><a href="Oxatomide.htm" tppabs="https://ptable.com/wiki/compounds/A/Oxatomide" title="Oxatomide">Oxatomide</a></li>
<li><a href="Paclitaxel.htm" tppabs="https://ptable.com/wiki/compounds/A/Paclitaxel" title="Paclitaxel">Paclitaxel</a></li>
<li><a href="Phenobarbital.htm" tppabs="https://ptable.com/wiki/compounds/A/Phenobarbital" title="Phenobarbital">Phenobarbital</a></li>
<li><a href="Piperine.htm" tppabs="https://ptable.com/wiki/compounds/A/Piperine" title="Piperine">Piperine</a></li>
<li><a href="Plicamycin.htm" tppabs="https://ptable.com/wiki/compounds/A/Plicamycin" title="Plicamycin">Plicamycin</a></li>
<li><a href="Prednisolone.htm" tppabs="https://ptable.com/wiki/compounds/A/Prednisolone" title="Prednisolone">Prednisolone</a></li>
<li><a href="Pregnanediol.htm" tppabs="https://ptable.com/wiki/compounds/A/Pregnanediol" title="Pregnanediol">Pregnanediol</a></li>
<li>Pregnanedione (5β-dihydroprogesterone)</li>
<li>Pregnanolone</li>
<li><a href="Pregnenolone.htm" tppabs="https://ptable.com/wiki/compounds/A/Pregnenolone" title="Pregnenolone">Pregnenolone</a></li>
<li>Pregnenolone 16α-carbonitrile</li>
<li>Proadifen</li>
<li><a href="Progesterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Progesterone" title="Progesterone">Progesterone</a></li>
<li>Quingestrone</li>
<li><a href="Reserpine.htm" tppabs="https://ptable.com/wiki/compounds/A/Reserpine" title="Reserpine">Reserpine</a></li>
<li>Reverse triiodothyronine</li>
<li><a href="Rifampicin.htm" tppabs="https://ptable.com/wiki/compounds/A/Rifampicin" title="Rifampicin">Rifampicin</a></li>
<li><a href="Rifaximin.htm" tppabs="https://ptable.com/wiki/compounds/A/Rifaximin" title="Rifaximin">Rifaximin</a></li>
<li><a href="Rimexolone.htm" tppabs="https://ptable.com/wiki/compounds/A/Rimexolone" title="Rimexolone">Rimexolone</a></li>
<li>Riodipine</li>
<li><a href="Ritonavir.htm" tppabs="https://ptable.com/wiki/compounds/A/Ritonavir" title="Ritonavir">Ritonavir</a></li>
<li><a href="Simvastatin.htm" tppabs="https://ptable.com/wiki/compounds/A/Simvastatin" title="Simvastatin">Simvastatin</a></li>
<li><a href="Sirolimus.htm" tppabs="https://ptable.com/wiki/compounds/A/Sirolimus" title="Sirolimus">Sirolimus</a></li>
<li><a href="Spironolactone.htm" tppabs="https://ptable.com/wiki/compounds/A/Spironolactone" title="Spironolactone">Spironolactone</a></li>
<li>Spiroxatrine</li>
<li><span class="new">SR-12813</span></li>
<li><span class="new">Suberoylanilide</span></li>
<li>Sulfisoxazole</li>
<li><a href="Suramin.htm" tppabs="https://ptable.com/wiki/compounds/A/Suramin" title="Suramin">Suramin</a></li>
<li><a href="Tacrolimus.htm" tppabs="https://ptable.com/wiki/compounds/A/Tacrolimus" title="Tacrolimus">Tacrolimus</a></li>
<li><span class="new">Tenylidone</span></li>
<li><a href="Terconazole.htm" tppabs="https://ptable.com/wiki/compounds/A/Terconazole" title="Terconazole">Terconazole</a></li>
<li>Testosterone isocaproate</li>
<li><a href="Tetracycline.htm" tppabs="https://ptable.com/wiki/compounds/A/Tetracycline" title="Tetracycline">Tetracycline</a></li>
<li>Thiamylal sodium</li>
<li><a href="Thiothixene.htm" tppabs="https://ptable.com/wiki/compounds/A/Thiothixene" title="Thiothixene" class="mw-redirect">Thiothixene</a></li>
<li>Thonzonium bromide</li>
<li>Tianeptine</li>
<li><a href="Troglitazone.htm" tppabs="https://ptable.com/wiki/compounds/A/Troglitazone" title="Troglitazone">Troglitazone</a></li>
<li><a href="Troleandomycin.htm" tppabs="https://ptable.com/wiki/compounds/A/Troleandomycin" title="Troleandomycin">Troleandomycin</a></li>
<li><span class="new">Tropanyl 3,5-dimethulbenzoate</span></li>
<li><a href="Zafirlukast.htm" tppabs="https://ptable.com/wiki/compounds/A/Zafirlukast" title="Zafirlukast">Zafirlukast</a></li>
<li><a href="Zeranol.htm" tppabs="https://ptable.com/wiki/compounds/A/Zeranol" title="Zeranol">Zeranol</a></li></ul>

<ul><li><i>Antagonists:</i> <a href="Ketoconazole.htm" tppabs="https://ptable.com/wiki/compounds/A/Ketoconazole" title="Ketoconazole">Ketoconazole</a></li>
<li><a href="Sesamin.htm" tppabs="https://ptable.com/wiki/compounds/A/Sesamin" title="Sesamin">Sesamin</a></li></ul>
</div></td></tr><tr><td class="navbox-abovebelow" colspan="2"><div>
<dl><dt>See also</dt>
<dd><i>Receptor/signaling modulators</i></dd></dl>
</div></td></tr></tbody></table></div><span>
</span>








<style data-mw-deduplicate="TemplateStyles:r951705291">.mw-parser-output cite.citation{font-style:inherit}.mw-parser-output .citation q{quotes:"\"""\"""'""'"}.mw-parser-output .id-lock-free a,.mw-parser-output .citation .cs1-lock-free a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .id-lock-limited a,.mw-parser-output .id-lock-registration a,.mw-parser-output .citation .cs1-lock-limited a,.mw-parser-output .citation .cs1-lock-registration a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .id-lock-subscription a,.mw-parser-output .citation .cs1-lock-subscription a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration{color:#555}.mw-parser-output .cs1-subscription span,.mw-parser-output .cs1-registration span{border-bottom:1px dotted;cursor:help}.mw-parser-output .cs1-ws-icon a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg*/);background-repeat:no-repeat;background-size:12px;background-position:right .1em center}.mw-parser-output code.cs1-code{color:inherit;background:inherit;border:inherit;padding:inherit}.mw-parser-output .cs1-hidden-error{display:none;font-size:100%}.mw-parser-output .cs1-visible-error{font-size:100%}.mw-parser-output .cs1-maint{display:none;color:#33aa33;margin-left:0.3em}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration,.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left,.mw-parser-output .cs1-kern-wl-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right,.mw-parser-output .cs1-kern-wl-right{padding-right:0.2em}.mw-parser-output .citation .mw-selflink{font-weight:inherit}</style>
    
</details></div>
        </div>
      </div>
    </div>
  </div>
  <script src="../-/j/js_modules/jsConfigVars.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/jsConfigVars.js" class=""></script>
  <script src="../-/j/js_modules/startup.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/startup.js" class=""></script>
<script src="../-/j/js_modules/jquery.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/jquery.js" class=""></script>
<script src="../-/j/js_modules/mediawiki.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/mediawiki.js" class=""></script>
<script src="../-/j/js_modules/site.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/site.js" class=""></script>
<script src="../-/j/js_modules/ext.cite.ux-enhancements.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/ext.cite.ux-enhancements.js" class=""></script>



</body></html>